var data={"title":"Methicillin-resistant Staphylococcus aureus in children: Treatment of invasive infections","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Methicillin-resistant Staphylococcus aureus in children: Treatment of invasive infections</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/contributors\" class=\"contributor contributor_credentials\">Sheldon L Kaplan, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/contributors\" class=\"contributor contributor_credentials\">Morven S Edwards, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/contributors\" class=\"contributor contributor_credentials\">Mary M Torchia, MD</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Sep 27, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Methicillin-resistant <em>Staphylococcus aureus</em> (MRSA, <a href=\"topic.htm?path=oxacillin-pediatric-drug-information\" class=\"drug drug_pediatric\">oxacillin</a> minimum inhibitory concentration [MIC] &ge;4 <span class=\"nowrap\">mcg/mL)</span> has increased in prevalence worldwide as both a healthcare-associated and a community-associated pathogen. Community-associated MRSA most frequently causes skin and soft-tissue infections [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/1,2\" class=\"abstract_t\">1,2</a>]. However, it is also associated with invasive infections, particularly pneumonia and musculoskeletal infections. (See <a href=\"topic.htm?path=methicillin-resistant-staphylococcus-aureus-infections-in-children-epidemiology-and-clinical-spectrum\" class=\"medical medical_review\">&quot;Methicillin-resistant Staphylococcus aureus infections in children: Epidemiology and clinical spectrum&quot;</a>.)</p><p>An increasing proportion of MRSA isolates are resistant to additional antimicrobial agents, which complicates therapy [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/3\" class=\"abstract_t\">3</a>]. The identification of <em>S. aureus</em> strains with intermediate and complete resistance to <a href=\"topic.htm?path=vancomycin-pediatric-drug-information\" class=\"drug drug_pediatric\">vancomycin</a> has raised particular concern. Children with infections due to such organisms should be managed in consultation with an expert in infectious diseases.</p><p>The treatment of invasive infections caused by MRSA, vancomycin-intermediate <em>S. aureus</em> (VISA), and vancomycin-resistant <em>S. aureus</em> (VRSA) in children will be reviewed here. The genetic mechanisms responsible for methicillin resistance; the epidemiology, prevention, and control of MRSA infections in children; and the treatment of MRSA skin and soft-tissue infections in children are discussed separately. (See <a href=\"topic.htm?path=methicillin-resistant-staphylococcus-aureus-mrsa-microbiology\" class=\"medical medical_review\">&quot;Methicillin-resistant Staphylococcus aureus (MRSA): Microbiology&quot;</a> and <a href=\"topic.htm?path=methicillin-resistant-staphylococcus-aureus-infections-in-children-epidemiology-and-clinical-spectrum\" class=\"medical medical_review\">&quot;Methicillin-resistant Staphylococcus aureus infections in children: Epidemiology and clinical spectrum&quot;</a> and <a href=\"topic.htm?path=suspected-staphylococcus-aureus-and-streptococcal-skin-and-soft-tissue-infections-in-children-greater-than28-days-evaluation-and-management\" class=\"medical medical_review\">&quot;Suspected Staphylococcus aureus and streptococcal skin and soft tissue infections in children &gt;28 days: Evaluation and management&quot;</a>.)</p><p>MRSA, VISA, and VRSA infections in adults also are discussed separately. (See <a href=\"topic.htm?path=methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia\" class=\"medical medical_review\">&quot;Methicillin-resistant Staphylococcus aureus (MRSA) in adults: Treatment of bacteremia&quot;</a> and <a href=\"topic.htm?path=methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-skin-and-soft-tissue-infections\" class=\"medical medical_review\">&quot;Methicillin-resistant Staphylococcus aureus (MRSA) in adults: Treatment of skin and soft tissue infections&quot;</a> and <a href=\"topic.htm?path=staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin\" class=\"medical medical_review\">&quot;Staphylococcus aureus bacteremia with reduced susceptibility to vancomycin&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H11\"><span class=\"h1\">TREATMENT APPROACH</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Clinical trials evaluating antimicrobial agents for invasive methicillin-resistant <em>S. aureus</em> (MRSA) infections in children are lacking. The treatment approach suggested in this topic review is based on case series, in vitro susceptibility testing, and the clinical experience of experts [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/4-6\" class=\"abstract_t\">4-6</a>].</p><p><a href=\"topic.htm?path=vancomycin-pediatric-drug-information\" class=\"drug drug_pediatric\">Vancomycin</a> alone (or in combination with other drugs, particularly for infections related to implanted devices) is the treatment of choice for severe MRSA infections [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/4,6\" class=\"abstract_t\">4,6</a>]. Alternative agents, many of which are relatively new and poorly studied in children, may be considered in the setting of adverse effects to vancomycin (<a href=\"image.htm?imageKey=PEDS%2F78349\" class=\"graphic graphic_table graphicRef78349 \">table 1</a>). </p><p>Given the limited number of antimicrobial agents with activity against MRSA and the increasing emergence of multidrug-resistant strains, treatment of suspected invasive MRSA infection in children is guided by a number of general principles:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Specimens for culture and antimicrobial susceptibility testing should be collected whenever possible before initiation of antimicrobial therapy [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/4,7\" class=\"abstract_t\">4,7</a>]. Aspiration or surgical incision and drainage of bone or joint infections should be performed within 48 hours of starting antibiotic treatment.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Quantitative antimicrobial susceptibility testing (to beta-lactam antibiotics, <a href=\"topic.htm?path=gentamicin-pediatric-drug-information\" class=\"drug drug_pediatric\">gentamicin</a>, <a href=\"topic.htm?path=trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information\" class=\"drug drug_pediatric\">trimethoprim-sulfamethoxazole</a> [TMP-SMX], tetracyclines, <a href=\"topic.htm?path=erythromycin-pediatric-drug-information\" class=\"drug drug_pediatric\">erythromycin</a>, <a href=\"topic.htm?path=clindamycin-pediatric-drug-information\" class=\"drug drug_pediatric\">clindamycin</a>, <a href=\"topic.htm?path=rifampin-rifampicin-pediatric-drug-information\" class=\"drug drug_pediatric\">rifampin</a>, <a href=\"topic.htm?path=vancomycin-pediatric-drug-information\" class=\"drug drug_pediatric\">vancomycin</a>, <a href=\"topic.htm?path=linezolid-pediatric-drug-information\" class=\"drug drug_pediatric\">linezolid</a>, and <a href=\"topic.htm?path=daptomycin-pediatric-drug-information\" class=\"drug drug_pediatric\">daptomycin</a>) and testing for clindamycin-inducible resistance should be performed for all staphylococci isolated from normally sterile sites [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/6,8,9\" class=\"abstract_t\">6,8,9</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Final therapy decisions should be based upon results of cultures and susceptibility testing [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/7\" class=\"abstract_t\">7</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Decisions regarding antimicrobial combinations should be individualized [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/4\" class=\"abstract_t\">4</a>]. There are no data from controlled trials establishing a benefit for combination therapy. Antimicrobial combinations possibly increase bactericidal activity and prevent the emergence of antimicrobial resistance during therapy [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/10,11\" class=\"abstract_t\">10,11</a>]. <a href=\"topic.htm?path=gentamicin-pediatric-drug-information\" class=\"drug drug_pediatric\">Gentamicin</a> and <a href=\"topic.htm?path=rifampin-rifampicin-pediatric-drug-information\" class=\"drug drug_pediatric\">rifampin</a> may be used as adjunctive agents in select circumstances (<a href=\"image.htm?imageKey=PEDS%2F78349\" class=\"graphic graphic_table graphicRef78349 \">table 1</a>) but should not be used as single-drug therapy. Gentamicin may be associated with greater nephrotoxicity.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Potential foci of infection (eg, intravascular catheters, purulent collections) should be removed or drained [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/5,12,13\" class=\"abstract_t\">5,12,13</a>]. Imaging studies may be necessary to identify foci of infection that require drainage [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/5\" class=\"abstract_t\">5</a>]. (See <a href=\"topic.htm?path=hematogenous-osteomyelitis-in-children-evaluation-and-diagnosis#H601786215\" class=\"medical medical_review\">&quot;Hematogenous osteomyelitis in children: Evaluation and diagnosis&quot;, section on 'Advanced imaging'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Consultation with an expert in infectious diseases is suggested for children with serious or life-threatening invasive infection [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/5,7\" class=\"abstract_t\">5,7</a>].</p><p/><p class=\"headingAnchor\" id=\"H12\"><span class=\"h1\">EMPIRIC THERAPY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Children with invasive staphylococcal infections should be hospitalized and treated, at least initially, with intravenous (IV) antimicrobial agents [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/7\" class=\"abstract_t\">7</a>].</p><p>Most healthcare-associated methicillin-resistant <em>S. aureus</em> (HA-MRSA) strains are multidrug resistant; most community-associated MRSA (CA-MRSA) strains are relatively susceptible to nonbeta-lactam antibiotics (eg, <a href=\"topic.htm?path=clindamycin-pediatric-drug-information\" class=\"drug drug_pediatric\">clindamycin</a>, <a href=\"topic.htm?path=trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information\" class=\"drug drug_pediatric\">trimethoprim-sulfamethoxazole</a>) [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/14-17\" class=\"abstract_t\">14-17</a>]. However, there is variability among CA-MRSA strains. Some are resistant to multiple drugs and some have susceptibility patterns similar to HA-MRSA isolates [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/3,18-21\" class=\"abstract_t\">3,18-21</a>].</p><p>The following factors should be considered when choosing empiric antimicrobial therapy for suspected staphylococcal infections in children (<a href=\"image.htm?imageKey=PEDS%2F61437\" class=\"graphic graphic_table graphicRef61437 \">table 2</a>) [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/4,6,22\" class=\"abstract_t\">4,6,22</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Severity and site of infection.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>History or risk of HA-MRSA acquisition; the isolates from children with identifiable risk factors for HA-MRSA are more likely to be resistant to <a href=\"topic.htm?path=clindamycin-pediatric-drug-information\" class=\"drug drug_pediatric\">clindamycin</a> than isolates from children without risk factors [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/23,24\" class=\"abstract_t\">23,24</a>]. (See <a href=\"topic.htm?path=methicillin-resistant-staphylococcus-aureus-infections-in-children-epidemiology-and-clinical-spectrum#H12\" class=\"medical medical_review\">&quot;Methicillin-resistant Staphylococcus aureus infections in children: Epidemiology and clinical spectrum&quot;, section on 'Epidemiology and risk factors'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Prevalence of MRSA in the community; empiric antibiotics should include coverage for MRSA if the proportion of <em>S. aureus</em> isolates is greater than 10 percent [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/8\" class=\"abstract_t\">8</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Antibiotic susceptibility of MRSA in the community; the rates vary from community to community [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/1,3,21,25,26\" class=\"abstract_t\">1,3,21,25,26</a>].</p><p/><p class=\"headingAnchor\" id=\"H13\"><span class=\"h2\">For critically ill</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>For children with life-threatening infections (eg, septicemia, endocarditis, overwhelming pneumonia, central nervous system infections, infections requiring admission to the intensive care unit) possibly due to <em>S. aureus</em>, we suggest empiric therapy with <a href=\"topic.htm?path=vancomycin-pediatric-drug-information\" class=\"drug drug_pediatric\">vancomycin</a> plus either <a href=\"topic.htm?path=nafcillin-pediatric-drug-information\" class=\"drug drug_pediatric\">nafcillin</a> or <a href=\"topic.htm?path=oxacillin-pediatric-drug-information\" class=\"drug drug_pediatric\">oxacillin</a>; <a href=\"topic.htm?path=gentamicin-pediatric-drug-information\" class=\"drug drug_pediatric\">gentamicin</a> or <a href=\"topic.htm?path=rifampin-rifampicin-pediatric-drug-information\" class=\"drug drug_pediatric\">rifampin</a> may be added for potential synergy in selected circumstances (<a href=\"image.htm?imageKey=PEDS%2F61437\" class=\"graphic graphic_table graphicRef61437 \">table 2</a>) [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/6,8,11,22\" class=\"abstract_t\">6,8,11,22</a>]. The combination of vancomycin plus nafcillin or oxacillin is recommended to maximize coverage for both MRSA and methicillin-susceptible <em>S. aureus</em> (MSSA). Additional antibiotics may be required for empiric treatment of non-staphylococcal pathogens until the pathogen is identified. (See <a href=\"#H284659487\" class=\"local\">'Vancomycin'</a> below.)</p><p>Single-drug therapy with <a href=\"topic.htm?path=linezolid-pediatric-drug-information\" class=\"drug drug_pediatric\">linezolid</a> is an alternative for children with pneumonia and without endovascular infection [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/4-6,27\" class=\"abstract_t\">4-6,27</a>]. <a href=\"topic.htm?path=ceftaroline-pediatric-drug-information\" class=\"drug drug_pediatric\">Ceftaroline</a> is also an option in this setting [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/28\" class=\"abstract_t\">28</a>].</p><p class=\"headingAnchor\" id=\"H14\"><span class=\"h2\">For serious infection</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Empiric antimicrobial therapy for children with non-life-threatening serious infections (eg, osteomyelitis, septic arthritis, pneumonia with empyema) possibly due to <em>S. aureus</em> depends upon the prevalence of MRSA infection in the community and whether the patient has risk factors for HA-MRSA (<a href=\"image.htm?imageKey=PEDS%2F61437\" class=\"graphic graphic_table graphicRef61437 \">table 2</a>) [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/4-6\" class=\"abstract_t\">4-6</a>].</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In communities where the prevalence of MRSA infection is low (eg, &lt;10 percent), <a href=\"topic.htm?path=nafcillin-pediatric-drug-information\" class=\"drug drug_pediatric\">nafcillin</a> or <a href=\"topic.htm?path=oxacillin-pediatric-drug-information\" class=\"drug drug_pediatric\">oxacillin</a> may be used for empiric therapy.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In communities where the prevalence of MRSA infection is high (eg, &gt;10 percent) and the prevalence of <a href=\"topic.htm?path=clindamycin-pediatric-drug-information\" class=\"drug drug_pediatric\">clindamycin</a> resistance is low, clindamycin may be used for empiric therapy if bacteremia is not likely [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/6,8\" class=\"abstract_t\">6,8</a>]. The threshold prevalence of clindamycin-resistant MRSA (constitutive plus inducible) for choosing <a href=\"topic.htm?path=vancomycin-pediatric-drug-information\" class=\"drug drug_pediatric\">vancomycin</a> varies from center to center, usually ranging from 10 to 25 percent, trying to balance the benefit of definitive therapy for the patient with the risk of increasing vancomycin resistance in the community. Additional considerations in the decision to choose vancomycin include the prevalence of MRSA in the community, the severity of illness, and the turn-around time for susceptibilities.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For children with risk factors for HA-MRSA infection, empiric therapy should include <a href=\"topic.htm?path=vancomycin-pediatric-drug-information\" class=\"drug drug_pediatric\">vancomycin</a> [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/6\" class=\"abstract_t\">6</a>]. (See <a href=\"topic.htm?path=methicillin-resistant-staphylococcus-aureus-infections-in-children-epidemiology-and-clinical-spectrum#H12\" class=\"medical medical_review\">&quot;Methicillin-resistant Staphylococcus aureus infections in children: Epidemiology and clinical spectrum&quot;, section on 'Epidemiology and risk factors'</a>.)</p><p/><p class=\"headingAnchor\" id=\"H15\"><span class=\"h3\">Bacteremia</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The treatment of <em>S. aureus</em> bacteremia in children is discussed separately. (See <a href=\"topic.htm?path=staphylococcus-aureus-bacteremia-in-children-management-and-outcome\" class=\"medical medical_review\">&quot;Staphylococcus aureus bacteremia in children: Management and outcome&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H16\"><span class=\"h3\">Osteomyelitis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Empiric antimicrobial therapy for children with osteomyelitis in communities with a high prevalence of CA-MRSA (ie, &gt;10 percent) usually includes <a href=\"topic.htm?path=vancomycin-pediatric-drug-information\" class=\"drug drug_pediatric\">vancomycin</a> or <a href=\"topic.htm?path=clindamycin-pediatric-drug-information\" class=\"drug drug_pediatric\">clindamycin</a>. Children in communities with a high prevalence of clindamycin resistance should receive vancomycin pending results of susceptibility testing, including testing for inducible resistance to clindamycin [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/29\" class=\"abstract_t\">29</a>]. (See <a href=\"#H284659711\" class=\"local\">'Inducible resistance'</a> below and <a href=\"topic.htm?path=hematogenous-osteomyelitis-in-children-management#H3\" class=\"medical medical_review\">&quot;Hematogenous osteomyelitis in children: Management&quot;, section on 'Empiric therapy'</a>.)</p><p class=\"headingAnchor\" id=\"H17\"><span class=\"h3\">Pneumonia</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Empiric treatment for suspected staphylococcal pneumonia in children should include <a href=\"topic.htm?path=vancomycin-pediatric-drug-information\" class=\"drug drug_pediatric\">vancomycin</a> if the child is critically ill. <a href=\"topic.htm?path=clindamycin-pediatric-drug-information\" class=\"drug drug_pediatric\">Clindamycin</a> is an alternative for children who are not critically ill in whom bacteremia is unlikely and if the prevalence of clindamycin resistance in the community is low. <a href=\"topic.htm?path=linezolid-pediatric-drug-information\" class=\"drug drug_pediatric\">Linezolid</a> is another option. General aspects of treatment of pneumonia in children are discussed separately. (See <a href=\"topic.htm?path=pneumonia-in-children-inpatient-treatment#H12\" class=\"medical medical_review\">&quot;Pneumonia in children: Inpatient treatment&quot;, section on 'Empiric therapy'</a> and <a href=\"topic.htm?path=community-acquired-pneumonia-in-children-outpatient-treatment#H3\" class=\"medical medical_review\">&quot;Community-acquired pneumonia in children: Outpatient treatment&quot;, section on 'Empiric therapy'</a> and <a href=\"topic.htm?path=management-and-prognosis-of-parapneumonic-effusion-and-empyema-in-children\" class=\"medical medical_review\">&quot;Management and prognosis of parapneumonic effusion and empyema in children&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H18\"><span class=\"h3\">Skin and soft tissue</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Treatment of suspected MRSA skin and soft-tissue infections is discussed separately. (See <a href=\"topic.htm?path=suspected-staphylococcus-aureus-and-streptococcal-skin-and-soft-tissue-infections-in-children-greater-than28-days-evaluation-and-management#H6\" class=\"medical medical_review\">&quot;Suspected Staphylococcus aureus and streptococcal skin and soft tissue infections in children &gt;28 days: Evaluation and management&quot;, section on 'Management approach'</a>.)</p><p class=\"headingAnchor\" id=\"H19\"><span class=\"h1\">DEFINITIVE THERAPY</span></p><p class=\"headingAnchor\" id=\"H20\"><span class=\"h2\">MRSA infections</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Methicillin resistance in <em>S. aureus</em> is defined as an <a href=\"topic.htm?path=oxacillin-pediatric-drug-information\" class=\"drug drug_pediatric\">oxacillin</a> minimum inhibitory concentration (MIC) &ge;4 <span class=\"nowrap\">mcg/mL</span>. Isolates resistant to oxacillin or methicillin also are resistant to all beta-lactam agents, including cephalosporins (with the exception of <a href=\"topic.htm?path=ceftaroline-pediatric-drug-information\" class=\"drug drug_pediatric\">ceftaroline</a> and ceftobiprole). Definitive therapy for invasive methicillin-resistant <em>S. aureus</em> (MRSA) infections depends upon results of susceptibility testing and the D test (<a href=\"image.htm?imageKey=PEDS%2F78349\" class=\"graphic graphic_table graphicRef78349 \">table 1</a>) [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/6,7\" class=\"abstract_t\">6,7</a>].</p><p>We suggest <a href=\"topic.htm?path=vancomycin-pediatric-drug-information\" class=\"drug drug_pediatric\">vancomycin</a> doses of 60 <span class=\"nowrap\">mg/kg</span> per day in four divided doses for children with invasive MRSA infections with vancomycin MICs &le;2 <span class=\"nowrap\">mcg/mL</span>. We do not use a loading dose of vancomycin for the first dose in children. (See <a href=\"#H284659487\" class=\"local\">'Vancomycin'</a> below.) </p><p class=\"headingAnchor\" id=\"H21\"><span class=\"h2\">VISA infections</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Vancomycin-intermediate <em>S. aureus</em> (VISA) is defined as a <a href=\"topic.htm?path=vancomycin-pediatric-drug-information\" class=\"drug drug_pediatric\">vancomycin</a> MIC 4 through 8 <span class=\"nowrap\">mcg/mL</span> [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/30,31\" class=\"abstract_t\">30,31</a>]. Optimal therapy for VISA infections in children has yet to be determined [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/6\" class=\"abstract_t\">6</a>]. The choice of antibiotics depends upon the results of in vitro susceptibility studies (<a href=\"image.htm?imageKey=PEDS%2F69174\" class=\"graphic graphic_table graphicRef69174 \">table 3</a>). Consultation with an expert in pediatric infectious diseases is suggested in the management of children with VISA infections [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/6\" class=\"abstract_t\">6</a>].</p><p>VISA strains have variable susceptibility patterns, with some still susceptible to <a href=\"topic.htm?path=linezolid-pediatric-drug-information\" class=\"drug drug_pediatric\">linezolid</a>, <a href=\"topic.htm?path=chloramphenicol-pediatric-drug-information\" class=\"drug drug_pediatric\">chloramphenicol</a>, <a href=\"topic.htm?path=gentamicin-pediatric-drug-information\" class=\"drug drug_pediatric\">gentamicin</a>, <a href=\"topic.htm?path=rifampin-rifampicin-pediatric-drug-information\" class=\"drug drug_pediatric\">rifampin</a>, <a href=\"topic.htm?path=trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information\" class=\"drug drug_pediatric\">trimethoprim-sulfamethoxazole</a>, or <a href=\"topic.htm?path=tetracycline-pediatric-drug-information\" class=\"drug drug_pediatric\">tetracycline</a> [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/32-34\" class=\"abstract_t\">32-34</a>]. VISA strains also show in vitro susceptibility to <a href=\"topic.htm?path=daptomycin-pediatric-drug-information\" class=\"drug drug_pediatric\">daptomycin</a>, <a href=\"topic.htm?path=quinupristin-and-dalfopristin-pediatric-drug-information\" class=\"drug drug_pediatric\">quinupristin-dalfopristin</a>, and <a href=\"topic.htm?path=ceftaroline-pediatric-drug-information\" class=\"drug drug_pediatric\">ceftaroline</a>, but clinical experience with these agents in children is limited [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/35-38\" class=\"abstract_t\">35-38</a>]. (See <a href=\"#H284659481\" class=\"local\">'Antimicrobial agents'</a> below.)</p><p>The initial case reported from Japan was treated with surgical debridement and <a href=\"topic.htm?path=ampicillin-and-sulbactam-pediatric-drug-information\" class=\"drug drug_pediatric\">ampicillin-sulbactam</a> plus an aminoglycoside [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/32\" class=\"abstract_t\">32</a>]. <a href=\"topic.htm?path=linezolid-pediatric-drug-information\" class=\"drug drug_pediatric\">Linezolid</a> and <a href=\"topic.htm?path=quinupristin-and-dalfopristin-pediatric-drug-information\" class=\"drug drug_pediatric\">quinupristin-dalfopristin</a> have been effective therapy for some VISA strains [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/39-41\" class=\"abstract_t\">39-41</a>]. (See <a href=\"topic.htm?path=staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin\" class=\"medical medical_review\">&quot;Staphylococcus aureus bacteremia with reduced susceptibility to vancomycin&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H22\"><span class=\"h2\">VRSA infections</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Vancomycin-resistant <em>S. aureus</em> (VRSA) is defined as a <a href=\"topic.htm?path=vancomycin-pediatric-drug-information\" class=\"drug drug_pediatric\">vancomycin</a> MIC &ge;16 <span class=\"nowrap\">mcg/mL</span> [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/30,31\" class=\"abstract_t\">30,31</a>]. VRSA strains have been susceptible to several other agents, including <a href=\"topic.htm?path=linezolid-pediatric-drug-information\" class=\"drug drug_pediatric\">linezolid</a>, <a href=\"topic.htm?path=quinupristin-and-dalfopristin-pediatric-drug-information\" class=\"drug drug_pediatric\">quinupristin-dalfopristin</a>, <a href=\"topic.htm?path=daptomycin-pediatric-drug-information\" class=\"drug drug_pediatric\">daptomycin</a>, and <a href=\"topic.htm?path=ceftaroline-pediatric-drug-information\" class=\"drug drug_pediatric\">ceftaroline</a> [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/39,40,42-44\" class=\"abstract_t\">39,40,42-44</a>]. Consultation with an expert in pediatric infectious diseases is suggested in the management of children with VRSA infections. (See <a href=\"topic.htm?path=staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin\" class=\"medical medical_review\">&quot;Staphylococcus aureus bacteremia with reduced susceptibility to vancomycin&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H23\"><span class=\"h1\">DURATION OF THERAPY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The duration of therapy for invasive MRSA infection depends upon the site, but usually is at least four weeks for endocarditis, osteomyelitis, necrotizing pneumonia, or disseminated infection [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/6\" class=\"abstract_t\">6</a>]. Parenteral therapy is recommended for the entire course in patients with endocarditis and central nervous system infections. Oral therapy may be used for a portion of the course in patients with other types of infection.</p><p class=\"headingAnchor\" id=\"H24\"><span class=\"h1\">TREATMENT OF NEONATES</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The Infectious Diseases Society of America provides guidance for the management of invasive methicillin-resistant <em>S. aureus</em> (MRSA) infections in infants (&le;28 days of age) [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/4\" class=\"abstract_t\">4</a>]. The guidelines are based upon observations from a single-institution review of 126 cases treated between 2001 and 2006 [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/45\" class=\"abstract_t\">45</a>].</p><p>We recommend hospital admission for infants &le;28 days who have been evaluated for invasive infection (ie, infections extending beyond the skin and soft tissues) [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/45\" class=\"abstract_t\">45</a>]. (See <a href=\"topic.htm?path=febrile-infant-younger-than-90-days-of-age-outpatient-evaluation\" class=\"medical medical_review\">&quot;Febrile infant (younger than 90 days of age): Outpatient evaluation&quot;</a>.)</p><p>Empiric antimicrobial therapy should be based upon the local susceptibility pattern of community-associated <em>S. aureus</em> isolates. The author's institution uses <a href=\"topic.htm?path=vancomycin-pediatric-drug-information\" class=\"drug drug_pediatric\">vancomycin</a>, <a href=\"topic.htm?path=nafcillin-pediatric-drug-information\" class=\"drug drug_pediatric\">nafcillin</a>, and <a href=\"topic.htm?path=gentamicin-pediatric-drug-information\" class=\"drug drug_pediatric\">gentamicin</a> (gentamicin to cover possible gram-negative enteric pathogens) for neonates with suspected invasive staphylococcal infection (<a href=\"image.htm?imageKey=PEDS%2F64140\" class=\"graphic graphic_table graphicRef64140 \">table 4</a>).</p><p>When MRSA infection has been confirmed, intravenous <a href=\"topic.htm?path=vancomycin-pediatric-drug-information\" class=\"drug drug_pediatric\">vancomycin</a> is preferred [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/4\" class=\"abstract_t\">4</a>]; <a href=\"topic.htm?path=clindamycin-pediatric-drug-information\" class=\"drug drug_pediatric\">clindamycin</a> or <a href=\"topic.htm?path=linezolid-pediatric-drug-information\" class=\"drug drug_pediatric\">linezolid</a> are alternatives for nonendovascular MRSA infections [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/6\" class=\"abstract_t\">6</a>]. Linezolid should be used in consultation with an expert in infectious diseases.</p><p>Neonates with invasive infection should complete antimicrobial therapy intravenously. General aspects of management of invasive infections in neonates are discussed separately. (See <a href=\"topic.htm?path=bacterial-meningitis-in-the-neonate-treatment-and-outcome\" class=\"medical medical_review\">&quot;Bacterial meningitis in the neonate: Treatment and outcome&quot;</a> and <a href=\"topic.htm?path=urinary-tract-infections-in-neonates\" class=\"medical medical_review\">&quot;Urinary tract infections in neonates&quot;</a> and <a href=\"topic.htm?path=neonatal-pneumonia\" class=\"medical medical_review\">&quot;Neonatal pneumonia&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H25\"><span class=\"h1\">TREATMENT FAILURE</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Some patients with invasive infections fail to respond to treatment with an agent to which their isolate is susceptible in vitro [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/5\" class=\"abstract_t\">5</a>]. Potential reasons for this include:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Reduced concentration at the site of infection [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/46-48\" class=\"abstract_t\">46-48</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Heteroresistance to <a href=\"topic.htm?path=vancomycin-pediatric-drug-information\" class=\"drug drug_pediatric\">vancomycin</a> (eg, subpopulations of organisms with reduced susceptibility). (See <a href=\"topic.htm?path=overview-of-antibacterial-susceptibility-testing#H1897544320\" class=\"medical medical_review\">&quot;Overview of antibacterial susceptibility testing&quot;, section on 'Heteroresistance'</a>.)</p><p/><p>Strategies to overcome these problems include the addition of adjunctive antimicrobial agents (eg, <a href=\"topic.htm?path=rifampin-rifampicin-pediatric-drug-information\" class=\"drug drug_pediatric\">rifampin</a>, <a href=\"topic.htm?path=gentamicin-pediatric-drug-information\" class=\"drug drug_pediatric\">gentamicin</a>) <span class=\"nowrap\">and/or</span> a change in antimicrobial therapy [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/6,10\" class=\"abstract_t\">6,10</a>]. In either case, consultation with an expert in pediatric infectious diseases is recommended.</p><p class=\"headingAnchor\" id=\"H284659481\"><span class=\"h1\">ANTIMICROBIAL AGENTS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=vancomycin-pediatric-drug-information\" class=\"drug drug_pediatric\">Vancomycin</a> is the treatment of choice for invasive methicillin-resistant <em>S. aureus</em> (MRSA) infections in children [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/6\" class=\"abstract_t\">6</a>]. A variety of other agents have been used in patients who are allergic to or unable to tolerate vancomycin. These include <a href=\"topic.htm?path=trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information\" class=\"drug drug_pediatric\">trimethoprim-sulfamethoxazole</a>, <a href=\"topic.htm?path=clindamycin-pediatric-drug-information\" class=\"drug drug_pediatric\">clindamycin</a>, <a href=\"topic.htm?path=linezolid-pediatric-drug-information\" class=\"drug drug_pediatric\">linezolid</a>, <a href=\"topic.htm?path=quinupristin-and-dalfopristin-pediatric-drug-information\" class=\"drug drug_pediatric\">quinupristin-dalfopristin</a>, and <a href=\"topic.htm?path=daptomycin-pediatric-drug-information\" class=\"drug drug_pediatric\">daptomycin</a> [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/6,7\" class=\"abstract_t\">6,7</a>]. <a href=\"topic.htm?path=ceftaroline-pediatric-drug-information\" class=\"drug drug_pediatric\">Ceftaroline</a> is an option for treatment of isolates with intermediate resistance to vancomycin.</p><p class=\"headingAnchor\" id=\"H284659487\"><span class=\"h2\">Vancomycin</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=vancomycin-pediatric-drug-information\" class=\"drug drug_pediatric\">Vancomycin</a> is a glycopeptide antibiotic that inhibits cell wall synthesis. It is the drug of choice for the treatment of many invasive infections caused by MRSA, given its efficacy, and relative safety profile (<a href=\"image.htm?imageKey=PEDS%2F78349\" class=\"graphic graphic_table graphicRef78349 \">table 1</a>) [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/4,6,7,49,50\" class=\"abstract_t\">4,6,7,49,50</a>]. It is also the agent for which there is the most clinical experience in treating a variety of invasive clinical syndromes (eg, pneumonia, endocarditis, meningitis) [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/51,52\" class=\"abstract_t\">51,52</a>]. </p><p>We suggest <a href=\"topic.htm?path=vancomycin-pediatric-drug-information\" class=\"drug drug_pediatric\">vancomycin</a> doses of 60 <span class=\"nowrap\">mg/kg</span> per day in four divided doses for children with invasive MRSA infections with vancomycin MICs &le;2 <span class=\"nowrap\">mcg/mL</span>. A loading dose of vancomycin (eg, 25 to 30 <span class=\"nowrap\">mg/kg)</span> is not recommended for children although it may be warranted for adults with serious infections (eg, bacteremia, infective endocarditis, osteomyelitis, meningitis, pneumonia, necrotizing fasciitis) possibly caused by MRSA [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/4\" class=\"abstract_t\">4</a>]. In a randomized trial in children, a loading dose of 30 <span class=\"nowrap\">mg/kg</span> did not result in earlier achievement of therapeutic trough concentrations [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/53\" class=\"abstract_t\">53</a>].</p><p>We generally do not try to achieve trough concentrations between 15 and 20 <span class=\"nowrap\">mcg/mL</span> as recommended by many experts for adult patients [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/4,54,55\" class=\"abstract_t\">4,54,55</a>]. Whether such levels are necessary or safe in children is unclear [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/56-63\" class=\"abstract_t\">56-63</a>]. In observational studies, achieving comparable concentrations in children has not been associated with improved outcomes but has been associated with increased risk of acute kidney injury [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/61-63\" class=\"abstract_t\">61-63</a>].</p><p>One or more adjunctive agents (eg, <a href=\"topic.htm?path=gentamicin-pediatric-drug-information\" class=\"drug drug_pediatric\">gentamicin</a>, <a href=\"topic.htm?path=rifampin-rifampicin-pediatric-drug-information\" class=\"drug drug_pediatric\">rifampin</a>) have been added to <a href=\"topic.htm?path=vancomycin-pediatric-drug-information\" class=\"drug drug_pediatric\">vancomycin</a> when treating life-threatening infections (eg, sepsis, central nervous system infection, endocarditis) (<a href=\"image.htm?imageKey=PEDS%2F78349\" class=\"graphic graphic_table graphicRef78349 \">table 1</a>) and infections caused by strains intermediately susceptible to vancomycin (<a href=\"image.htm?imageKey=PEDS%2F69174\" class=\"graphic graphic_table graphicRef69174 \">table 3</a>) [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/6\" class=\"abstract_t\">6</a>]. However, there are no data from controlled trials establishing a benefit for combination therapy. The addition of gentamicin may lead to greater nephrotoxicity without any evidence of benefit. The author of this topic review does not recommend adjunctive antimicrobial agents in the absence of implanted devices. (See <a href=\"#H13\" class=\"local\">'For critically ill'</a> above and <a href=\"#H21\" class=\"local\">'VISA infections'</a> above.)</p><p>Although <a href=\"topic.htm?path=vancomycin-pediatric-drug-information\" class=\"drug drug_pediatric\">vancomycin</a> is generally efficacious for the treatment of MRSA, it is less effective than beta-lactams for methicillin-susceptible <em>S. aureus</em> (MSSA) [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/64-66\" class=\"abstract_t\">64-66</a>]. Thus, once results of susceptibility testing are known, <em>S. aureus</em> isolates that are methicillin- or penicillin-susceptible should be treated with beta-lactams rather than vancomycin (<a href=\"image.htm?imageKey=PEDS%2F57379\" class=\"graphic graphic_table graphicRef57379 \">table 5</a>) [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/6\" class=\"abstract_t\">6</a>].</p><p>Isolates of MRSA with intermediate susceptibility to <a href=\"topic.htm?path=vancomycin-pediatric-drug-information\" class=\"drug drug_pediatric\">vancomycin</a> and vancomycin resistance have been reported. Such isolates have been rarely reported in children [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/67\" class=\"abstract_t\">67</a>]. The identification of these strains poses additional therapeutic dilemmas. A greater concern is the increasing identification of <em>S. aureus</em> isolates that do not respond to vancomycin therapy in vivo but are not vancomycin resistant by minimum inhibitory concentration (MIC) determinations [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/68-70\" class=\"abstract_t\">68-70</a>]. (See <a href=\"topic.htm?path=staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin\" class=\"medical medical_review\">&quot;Staphylococcus aureus bacteremia with reduced susceptibility to vancomycin&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H284659633\"><span class=\"h2\">Clindamycin</span></p><p class=\"headingAnchor\" id=\"H2497450507\"><span class=\"h3\">Indications</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=clindamycin-pediatric-drug-information\" class=\"drug drug_pediatric\">Clindamycin</a> has been effective in the treatment of community-associated MRSA infections in children [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/18,71-73\" class=\"abstract_t\">18,71-73</a>]. It is a drug of choice for MRSA pneumonia, septic arthritis, and osteomyelitis if the isolate is susceptible, the D-test or automated testing for clindamycin resistance is negative (<a href=\"image.htm?imageKey=ID%2F114732\" class=\"graphic graphic_picture graphicRef114732 \">picture 1</a>), and blood cultures are negative (<a href=\"image.htm?imageKey=PEDS%2F78349\" class=\"graphic graphic_table graphicRef78349 \">table 1</a>) [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/6\" class=\"abstract_t\">6</a>] (see <a href=\"#H284659711\" class=\"local\">'Inducible resistance'</a> below). Clindamycin is well absorbed orally, so therapy can be completed orally (when clinically appropriate) [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/8\" class=\"abstract_t\">8</a>].</p><p><a href=\"topic.htm?path=clindamycin-pediatric-drug-information\" class=\"drug drug_pediatric\">Clindamycin</a> is also an option for initial empiric therapy for non-life-threatening <em>S. aureus</em> infection when rates of MRSA colonization and infection in the community are substantial (eg, &gt;10 percent) and the prevalence of clindamycin resistance is low (<a href=\"image.htm?imageKey=PEDS%2F61437\" class=\"graphic graphic_table graphicRef61437 \">table 2</a>) [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/6\" class=\"abstract_t\">6</a>]. Clindamycin should <strong>not</strong> be used for empiric treatment of invasive infections in communities with high rates of clindamycin resistance (constitutive plus inducible), as treatment failures have occurred [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/18,19,74\" class=\"abstract_t\">18,19,74</a>]. The threshold prevalence of clindamycin-resistant MRSA for choosing <a href=\"topic.htm?path=vancomycin-pediatric-drug-information\" class=\"drug drug_pediatric\">vancomycin</a> varies from center to center, usually ranging from 10 to 25 percent, trying to balance the benefit of definitive therapy for the patient with the risk of increasing vancomycin resistance in the community. Additional considerations in the decision to choose vancomycin include the prevalence of MRSA in the community, the severity of illness, and the turn-around time for susceptibilities.</p><p><a href=\"topic.htm?path=clindamycin-pediatric-drug-information\" class=\"drug drug_pediatric\">Clindamycin</a> also should <strong>not</strong> be used in patients with risk factors for healthcare-associated MRSA (HA-MRSA) since many of these strains are resistant to clindamycin [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/23,24\" class=\"abstract_t\">23,24</a>]. (See <a href=\"topic.htm?path=methicillin-resistant-staphylococcus-aureus-infections-in-children-epidemiology-and-clinical-spectrum#H8\" class=\"medical medical_review\">&quot;Methicillin-resistant Staphylococcus aureus infections in children: Epidemiology and clinical spectrum&quot;, section on 'Microbiologic characteristics'</a>.)</p><p class=\"headingAnchor\" id=\"H284659711\"><span class=\"h3\">Inducible resistance</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Resistance to <a href=\"topic.htm?path=clindamycin-pediatric-drug-information\" class=\"drug drug_pediatric\">clindamycin</a> may emerge during therapy in strains of MRSA with the inducible macrolide-lincosamide-streptogramin B (MLS)-resistance mechanism. MRSA isolates with the inducible MLS resistance mechanism appear susceptible to clindamycin and resistant to <a href=\"topic.htm?path=erythromycin-pediatric-drug-information\" class=\"drug drug_pediatric\">erythromycin</a> by most standard techniques, but can be detected using the &quot;D test&quot; (<a href=\"image.htm?imageKey=ID%2F114732\" class=\"graphic graphic_picture graphicRef114732 \">picture 1</a>) [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/75\" class=\"abstract_t\">75</a>]. In addition, automated systems are available that can screen for inducible resistance to clindamycin with results comparable to the standard D-test [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/29\" class=\"abstract_t\">29</a>]. (See <a href=\"topic.htm?path=overview-of-antibacterial-susceptibility-testing#H3812729230\" class=\"medical medical_review\">&quot;Overview of antibacterial susceptibility testing&quot;, section on 'Inducible clindamycin resistance testing'</a>.)</p><p><a href=\"topic.htm?path=clindamycin-pediatric-drug-information\" class=\"drug drug_pediatric\">Clindamycin</a> is best avoided when the isolates are D-zone positive. This is particularly true if a large inoculum of organisms is expected or antibiotics cannot easily reach the site of a deep infection [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/76\" class=\"abstract_t\">76</a>].</p><p class=\"headingAnchor\" id=\"H284659717\"><span class=\"h2\">Linezolid</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=linezolid-pediatric-drug-information\" class=\"drug drug_pediatric\">Linezolid</a> is an oxazolidinone antibiotic active against many antibiotic-resistant gram-positive cocci. It inhibits bacterial protein synthesis, thereby preventing formation of the 70S initiation complex. Linezolid is approved by the US Food and Drug Administration (FDA) for use in healthcare-associated pneumonia and complicated skin infections, including cases caused by MRSA (<a href=\"image.htm?imageKey=PEDS%2F63973\" class=\"graphic graphic_table graphicRef63973 \">table 6</a>) [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/52,77\" class=\"abstract_t\">52,77</a>]. It is bacteriostatic for <em>S. aureus</em> and thus is not routinely recommended for treatment of MRSA bacteremia or catheter-related bacteremia [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/78\" class=\"abstract_t\">78</a>]. Linezolid has not been well studied in the treatment of osteomyelitis [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/8\" class=\"abstract_t\">8</a>], although one case series in children reported linezolid to be effective in several patients [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/79\" class=\"abstract_t\">79</a>]. Isolated cases of linezolid-resistant MRSA and apparent failures of linezolid to treat or prevent endocarditis in patients with intravascular MRSA infection have been described [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/80-84\" class=\"abstract_t\">80-84</a>].</p><p><a href=\"topic.htm?path=linezolid-pediatric-drug-information\" class=\"drug drug_pediatric\">Linezolid</a> is an alternative to <a href=\"topic.htm?path=vancomycin-pediatric-drug-information\" class=\"drug drug_pediatric\">vancomycin</a> in children with serious MRSA infections when susceptibility testing has indicated that the isolate is susceptible (<a href=\"image.htm?imageKey=PEDS%2F78349\" class=\"graphic graphic_table graphicRef78349 \">table 1</a>) [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/6\" class=\"abstract_t\">6</a>]. It also can be used, in conjunction with either <a href=\"topic.htm?path=gentamicin-pediatric-drug-information\" class=\"drug drug_pediatric\">gentamicin</a> or <a href=\"topic.htm?path=rifampin-rifampicin-pediatric-drug-information\" class=\"drug drug_pediatric\">rifampin</a>, in children with vancomycin-intermediate <em>S. aureus</em> (VISA) (<a href=\"image.htm?imageKey=PEDS%2F69174\" class=\"graphic graphic_table graphicRef69174 \">table 3</a>). Consultation with an expert in infectious diseases is suggested before use of linezolid [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/6,7\" class=\"abstract_t\">6,7</a>]. Linezolid is well absorbed orally, so therapy can be completed orally (when clinically appropriate) [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/8\" class=\"abstract_t\">8</a>].</p><p><a href=\"topic.htm?path=linezolid-pediatric-drug-information\" class=\"drug drug_pediatric\">Linezolid</a> was equivalent to <a href=\"topic.htm?path=vancomycin-pediatric-drug-information\" class=\"drug drug_pediatric\">vancomycin</a> for the treatment of serious MRSA infections in a randomized, open-label trial in adults [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/51\" class=\"abstract_t\">51</a>]. Experience with linezolid for the treatment of staphylococcal infections in children is limited, but growing [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/52,79,85,86\" class=\"abstract_t\">52,79,85,86</a>]. It was equivalent to vancomycin for MRSA in a randomized trial in 321 hospitalized children (0 to 11 years) with gram-positive pneumonia, bacteremia, or complicated skin infections [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/52\" class=\"abstract_t\">52</a>]. The overall clinical cure rates were 79 and 74 percent for linezolid and vancomycin, respectively. Among patients with MRSA, clinical cure rates were 94 and 90 percent, and bacteriologic cure rates were 88 and 90 percent, respectively [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/86\" class=\"abstract_t\">86</a>]. A similarly designed trial in neonates also found linezolid to be well tolerated and as effective as vancomycin in the treatment of resistant gram-positive infections [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/85\" class=\"abstract_t\">85</a>].</p><p><a href=\"topic.htm?path=linezolid-pediatric-drug-information\" class=\"drug drug_pediatric\">Linezolid</a> resistance and linezolid failure have been described [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/81,82,87,88\" class=\"abstract_t\">81,82,87,88</a>]. In two case reports, endocarditis developed during treatment for MRSA infection [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/81\" class=\"abstract_t\">81</a>], and relapse of clinical infection occurred in a patient treated with linezolid for the final weeks of endocarditis therapy following echocardiographic resolution of the vegetation [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/82\" class=\"abstract_t\">82</a>]. An outbreak has also been described in an intensive care setting; reduction of linezolid use and infection control measures were associated with termination of the outbreak [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/88\" class=\"abstract_t\">88</a>].</p><p>Few adverse effects have been reported with <a href=\"topic.htm?path=linezolid-pediatric-drug-information\" class=\"drug drug_pediatric\">linezolid</a> in children; the most common side effects are rash, nausea, vomiting, and thrombocytopenia (which appears to be associated with renal impairment) [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/89-93\" class=\"abstract_t\">89-93</a>]. In adult patients, thrombocytopenia is associated with duration of therapy &gt;2 weeks; if the duration of therapy in children is &gt;2 weeks, complete blood count should be monitored [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/92,94,95\" class=\"abstract_t\">92,94,95</a>].</p><p>Less common adverse effects include optic neuritis, neuropathy, metabolic acidosis, and serotonin syndrome when administered concurrently with serotonergic agents [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/8,96,97\" class=\"abstract_t\">8,96,97</a>]. (See <a href=\"topic.htm?path=serotonin-syndrome-serotonin-toxicity\" class=\"medical medical_review\">&quot;Serotonin syndrome (serotonin toxicity)&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H284659723\"><span class=\"h2\">Quinupristin-dalfopristin</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=quinupristin-and-dalfopristin-pediatric-drug-information\" class=\"drug drug_pediatric\">Quinupristin-dalfopristin</a> is a streptogramin antibiotic. It is approved by the FDA for the treatment of vancomycin-resistant enterococcal infections and complicated skin infections caused by MSSA in adults and children &gt;16 years of age. It also has activity against MRSA and VISA isolates, although MRSA resistance has been described rarely [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/98\" class=\"abstract_t\">98</a>]. There may be synergy against MRSA when quinupristin-dalfopristin is combined with beta-lactams, and additive activity when combined with <a href=\"topic.htm?path=vancomycin-pediatric-drug-information\" class=\"drug drug_pediatric\">vancomycin</a> [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/99,100\" class=\"abstract_t\">99,100</a>].</p><p><a href=\"topic.htm?path=quinupristin-and-dalfopristin-pediatric-drug-information\" class=\"drug drug_pediatric\">Quinupristin-dalfopristin</a> is an alternative to <a href=\"topic.htm?path=vancomycin-pediatric-drug-information\" class=\"drug drug_pediatric\">vancomycin</a> in children with serious MRSA infections when susceptibility testing has indicated that the isolate is susceptible (<a href=\"image.htm?imageKey=PEDS%2F78349\" class=\"graphic graphic_table graphicRef78349 \">table 1</a>) [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/6\" class=\"abstract_t\">6</a>]. It also can be used, in conjunction with either <a href=\"topic.htm?path=gentamicin-pediatric-drug-information\" class=\"drug drug_pediatric\">gentamicin</a> or <a href=\"topic.htm?path=rifampin-rifampicin-pediatric-drug-information\" class=\"drug drug_pediatric\">rifampin</a>, in children with VISA (<a href=\"image.htm?imageKey=PEDS%2F69174\" class=\"graphic graphic_table graphicRef69174 \">table 3</a>) (see <a href=\"#H21\" class=\"local\">'VISA infections'</a> above). Consultation with an expert in infectious diseases is suggested before use of quinupristin-dalfopristin [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/6,7\" class=\"abstract_t\">6,7</a>].</p><p><a href=\"topic.htm?path=quinupristin-and-dalfopristin-pediatric-drug-information\" class=\"drug drug_pediatric\">Quinupristin-dalfopristin</a> activity against MRSA in adults was demonstrated in a series of 90 patients with MRSA bone, joint, skin, or soft-tissue infections who did not tolerate or had failed <a href=\"topic.htm?path=vancomycin-pediatric-drug-information\" class=\"drug drug_pediatric\">vancomycin</a> therapy; the overall response rate was 71 percent [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/39\" class=\"abstract_t\">39</a>]. Experience with quinupristin-dalfopristin in children is limited [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/6,101\" class=\"abstract_t\">6,101</a>].</p><p>Administration of <a href=\"topic.htm?path=quinupristin-and-dalfopristin-pediatric-drug-information\" class=\"drug drug_pediatric\">quinupristin-dalfopristin</a> requires central venous access. Adverse effects include hyperbilirubinemia, myalgias, arthralgias, and nausea.</p><p class=\"headingAnchor\" id=\"H284659729\"><span class=\"h2\">Daptomycin</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=daptomycin-pediatric-drug-information\" class=\"drug drug_pediatric\">Daptomycin</a> is a cyclic lipopeptide antibiotic that causes depolarization of the bacterial cell membrane and is bactericidal for <em>S. aureus</em> [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/4,102,103\" class=\"abstract_t\">4,102,103</a>]. It is approved by the FDA for treatment of patients &gt;1 year of age with complicated skin and skin-structure infections, children age 1 through 17 years with <em>S. aureus</em> bloodstream infections, and patients &ge;18 years of age with <em>S. aureus</em> bacteremia (including right-sided endocarditis) [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/104-107\" class=\"abstract_t\">104-107</a>]. Daptomycin should not be used for treatment of MRSA pneumonia since its activity is inhibited by pulmonary surfactant [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/103,108\" class=\"abstract_t\">103,108</a>].</p><p><a href=\"topic.htm?path=daptomycin-pediatric-drug-information\" class=\"drug drug_pediatric\">Daptomycin</a> has activity against MRSA, as well as against other resistant gram-positive bacteria [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/35,102,103\" class=\"abstract_t\">35,102,103</a>], and has been effective in animal models of MRSA infection [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/109\" class=\"abstract_t\">109</a>]. Daptomycin is one of the drugs of choice for treating VISA (<a href=\"image.htm?imageKey=PEDS%2F69174\" class=\"graphic graphic_table graphicRef69174 \">table 3</a>) [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/6\" class=\"abstract_t\">6</a>]. (See <a href=\"#H21\" class=\"local\">'VISA infections'</a> above.)</p><p>For complicated skin and skin structure infection in children, <a href=\"topic.htm?path=daptomycin-pediatric-drug-information\" class=\"drug drug_pediatric\">daptomycin</a> is administered intravenously once every 24 hours for up to 14 days [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/107\" class=\"abstract_t\">107</a>]. The recommended dose varies with age: </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>12 through 23 months &ndash; 10 <span class=\"nowrap\">mg/kg</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>2 through 6 years &ndash; 9 <span class=\"nowrap\">mg/kg</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>7 through 11 years &ndash; 7 <span class=\"nowrap\">mg/kg</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>12 through 17 years &ndash; 5 <span class=\"nowrap\">mg/kg</span></p><p/><p>For <em>S. aureus</em> bacteremia in children, <a href=\"topic.htm?path=daptomycin-pediatric-drug-information\" class=\"drug drug_pediatric\">daptomycin</a> is administered intravenously once every 24 hours for up to 42 days [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/107\" class=\"abstract_t\">107</a>]. The recommended dose varies with age: </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>1 through 6 years &ndash; 12 <span class=\"nowrap\">mg/kg</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>7 through 11 years &ndash; 9 <span class=\"nowrap\">mg/kg</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>12 through 17 years &ndash; 7 <span class=\"nowrap\">mg/kg</span></p><p/><p>The optimal dose of <a href=\"topic.htm?path=daptomycin-pediatric-drug-information\" class=\"drug drug_pediatric\">daptomycin</a> for children with other serious infections has yet to be determined [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/110,111\" class=\"abstract_t\">110,111</a>]. However, a 9 <span class=\"nowrap\">mg/kg</span> single daily dose results in area-under-the-concentration-time curve (AUC) values similar to AUC values associated with effective treatment in adults [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/112\" class=\"abstract_t\">112</a>].</p><p>In a multicenter randomized trial, initial treatment with <a href=\"topic.htm?path=daptomycin-pediatric-drug-information\" class=\"drug drug_pediatric\">daptomycin</a> was safe and well-tolerated in children between 1 and 17 years of age who had complicated skin and skin structure infections (ie, deep soft tissue infections, infections requiring significant surgical intervention, infections in patients with underlying conditions likely to complicate treatment response) [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/113\" class=\"abstract_t\">113</a>]. Daptomycin also appeared to be as effective as initial treatment with standard-of-care treatment (typically <a href=\"topic.htm?path=vancomycin-pediatric-drug-information\" class=\"drug drug_pediatric\">vancomycin</a> or <a href=\"topic.htm?path=clindamycin-pediatric-drug-information\" class=\"drug drug_pediatric\">clindamycin</a>) in achieving clinical cure (complete or partial resolution of signs and symptoms), but the trial was not powered to confirm noninferiority.</p><p>In a retrospective review from one institution, 16 children (median age 6.5 years) were treated with <a href=\"topic.htm?path=daptomycin-pediatric-drug-information\" class=\"drug drug_pediatric\">daptomycin</a> for treatment of invasive gram-positive bacterial infection [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/35\" class=\"abstract_t\">35</a>]: 15 had invasive staphylococcal disease, 1 with MSSA and 14 with MRSA (13 with community-associated MRSA). Twelve of the children with disseminated staphylococcal infection had persistent bacteremia despite therapy with at least two drugs (<a href=\"topic.htm?path=vancomycin-pediatric-drug-information\" class=\"drug drug_pediatric\">vancomycin</a>, <a href=\"topic.htm?path=clindamycin-pediatric-drug-information\" class=\"drug drug_pediatric\">clindamycin</a>, <a href=\"topic.htm?path=rifampin-rifampicin-pediatric-drug-information\" class=\"drug drug_pediatric\">rifampin</a>, aminoglycoside, <span class=\"nowrap\">and/or</span> <a href=\"topic.htm?path=linezolid-pediatric-drug-information\" class=\"drug drug_pediatric\">linezolid</a>); the addition of daptomycin resulted in bacteriologic cure in six of seven evaluable patients with persistent bacteremia. Daptomycin may be warranted in children with persistent bacteremia (&ge;4 days) in the absence of pulmonary involvement. Daptomycin should not be coadministered with vancomycin due to concerns for daptomycin resistance being induced by vancomycin [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/114,115\" class=\"abstract_t\">114,115</a>]. MRSA susceptibilities to daptomycin should be closely followed during treatment with daptomycin [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/115\" class=\"abstract_t\">115</a>].</p><p>Trials of the safety, efficacy, and pharmacokinetics of <a href=\"topic.htm?path=daptomycin-pediatric-drug-information\" class=\"drug drug_pediatric\">daptomycin</a> in children are ongoing, including a study of acute hematogenous osteomyelitis employing daily daptomycin doses of 7, 9, or 12 <span class=\"nowrap\">mg/kg</span> [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/116\" class=\"abstract_t\">116</a>].</p><p class=\"headingAnchor\" id=\"H284659735\"><span class=\"h2\">Trimethoprim-sulfamethoxazole</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information\" class=\"drug drug_pediatric\">Trimethoprim-sulfamethoxazole</a> (TMP-SMX) is a possible consideration in very selected children with nonserious MRSA infections when susceptibility testing has indicated that the isolate is susceptible to TMP-SMX (<a href=\"image.htm?imageKey=PEDS%2F78349\" class=\"graphic graphic_table graphicRef78349 \">table 1</a>) [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/6\" class=\"abstract_t\">6</a>].</p><p>There are no studies of the efficacy of TMP-SMX in invasive MRSA infections in children, although it has been effective in treating MSSA infections in children and adults [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/117-119\" class=\"abstract_t\">117-119</a>]. In a randomized trial comparing TMP-SMX and <a href=\"topic.htm?path=vancomycin-pediatric-drug-information\" class=\"drug drug_pediatric\">vancomycin</a> for the treatment of serious <em>S. aureus </em>infections in intravenous drug users, TMP-SMX was less effective than vancomycin; nonetheless, it resulted in bacteriologic cure in 86 percent of patients with MRSA (compared to 98 percent with vancomycin) [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/120\" class=\"abstract_t\">120</a>]. In another randomized trial, TMP-SMX did not achieve noninferiority compared with vancomycin for severe MRSA infections in adults, particularly MRSA bacteremia [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/121\" class=\"abstract_t\">121</a>].</p><p class=\"headingAnchor\" id=\"H425217035\"><span class=\"h2\">Ceftaroline</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=ceftaroline-pediatric-drug-information\" class=\"drug drug_pediatric\">Ceftaroline</a> is a parenteral cephalosporin that binds to penicillin-binding proteins. It approved by the FDA for treatment of complicated skin and skin structure infections, including those caused by MRSA, and treatment of community-acquired bacterial pneumonia (not including those caused by MRSA) in patients &ge;2 months of age [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/122\" class=\"abstract_t\">122</a>].</p><p>It has antimicrobial activity against <em>S. aureus</em> (including methicillin-resistant <em>S. aureus</em> [MRSA], vancomycin-intermediate <em>S. aureus</em>, and vancomycin-resistant <em>S. aureus), </em>other gram-positive bacteria, and gram-negative respiratory pathogens [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/28,123\" class=\"abstract_t\">28,123</a>]. It is one of the drugs of choice for treating VISA (<a href=\"image.htm?imageKey=PEDS%2F69174\" class=\"graphic graphic_table graphicRef69174 \">table 3</a>) [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/6\" class=\"abstract_t\">6</a>]. (See <a href=\"#H21\" class=\"local\">'VISA infections'</a> above.)</p><p>Experience with <a href=\"topic.htm?path=ceftaroline-pediatric-drug-information\" class=\"drug drug_pediatric\">ceftaroline</a> in children is limited [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/124-126\" class=\"abstract_t\">124-126</a>]. Additional trials of the safety, efficacy, and pharmacokinetics are ongoing [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/127,128\" class=\"abstract_t\">127,128</a>] to help determine the role of ceftaroline in the treatment of invasive MRSA infections in children and adults.</p><p class=\"headingAnchor\" id=\"H284659741\"><span class=\"h2\">Investigational therapies</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Investigational therapies for MRSA including glycopeptide agents and ceftobiprole are discussed separately. (See <a href=\"topic.htm?path=methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia#H1666912120\" class=\"medical medical_review\">&quot;Methicillin-resistant Staphylococcus aureus (MRSA) in adults: Treatment of bacteremia&quot;, section on 'Drugs with activity against MRSA'</a>.)</p><p class=\"headingAnchor\" id=\"H4093177008\"><span class=\"h1\">SOCIETY GUIDELINE LINKS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See <a href=\"topic.htm?path=society-guideline-links-methicillin-resistant-staphylococcus-aureus\" class=\"medical medical_society_guidelines\">&quot;Society guideline links: Methicillin-resistant Staphylococcus aureus&quot;</a>.)</p><p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\"><span class=\"h1\">INFORMATION FOR PATIENTS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>UpToDate offers two types of patient education materials, &quot;The Basics&quot; and &quot;Beyond the Basics.&quot; The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &quot;patient info&quot; and the keyword(s) of interest.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Beyond the Basics topics (see <a href=\"topic.htm?path=methicillin-resistant-staphylococcus-aureus-mrsa-beyond-the-basics\" class=\"medical medical_patient\">&quot;Patient education: Methicillin-resistant Staphylococcus aureus (MRSA) (Beyond the Basics)&quot;</a>)</p><p/><p class=\"headingAnchor\" id=\"H27\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The treatment of invasive methicillin-resistant <em>Staphylococcus aureus</em> (MRSA) infection is guided by quantitative antimicrobial susceptibility testing; we recommend that such testing be performed on all staphylococci isolated from normally sterile sites. (See <a href=\"#H11\" class=\"local\">'Treatment approach'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Adjunctive treatment requires removal or drainage of potential foci of infection (eg, intravascular catheters, purulent collections). (See <a href=\"#H11\" class=\"local\">'Treatment approach'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For children with suspected staphylococcal infections that are life threatening, we suggest empiric therapy with <a href=\"topic.htm?path=vancomycin-pediatric-drug-information\" class=\"drug drug_pediatric\">vancomycin</a> plus either <a href=\"topic.htm?path=nafcillin-pediatric-drug-information\" class=\"drug drug_pediatric\">nafcillin</a> or <a href=\"topic.htm?path=oxacillin-pediatric-drug-information\" class=\"drug drug_pediatric\">oxacillin</a>&nbsp;(<a href=\"grade.htm?i=5\" class=\"grade\">Grade 2B</a>); <a href=\"topic.htm?path=gentamicin-pediatric-drug-information\" class=\"drug drug_pediatric\">gentamicin</a> or <a href=\"topic.htm?path=rifampin-rifampicin-pediatric-drug-information\" class=\"drug drug_pediatric\">rifampin</a> may be added for synergy in select circumstances (<a href=\"image.htm?imageKey=PEDS%2F61437\" class=\"graphic graphic_table graphicRef61437 \">table 2</a>). <a href=\"topic.htm?path=linezolid-pediatric-drug-information\" class=\"drug drug_pediatric\">Linezolid</a> is an alternative for patients with pneumonia. (See <a href=\"#H13\" class=\"local\">'For critically ill'</a> above and <a href=\"#H284659487\" class=\"local\">'Vancomycin'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For children with non-life-threatening but serious infections possibly caused by <em>S. aureus</em>, empiric therapy depends upon the prevalence of MRSA in the community and whether the child has risk factors for healthcare-associated (HA-) MRSA (<a href=\"image.htm?imageKey=PEDS%2F61437\" class=\"graphic graphic_table graphicRef61437 \">table 2</a>):</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>If the prevalence of MRSA infection is &lt;10 percent, we suggest empiric therapy with <a href=\"topic.htm?path=nafcillin-pediatric-drug-information\" class=\"drug drug_pediatric\">nafcillin</a> or <a href=\"topic.htm?path=oxacillin-pediatric-drug-information\" class=\"drug drug_pediatric\">oxacillin</a> (<a href=\"grade.htm?i=5\" class=\"grade\">Grade 2B</a>). (See <a href=\"#H12\" class=\"local\">'Empiric therapy'</a> above.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>If the prevalence of MRSA infection is &gt;10 percent and the prevalence of <a href=\"topic.htm?path=clindamycin-pediatric-drug-information\" class=\"drug drug_pediatric\">clindamycin</a> resistance is low, we suggest empiric therapy with clindamycin (<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>). The threshold prevalence of clindamycin-resistant MRSA (constitutive plus inducible) for choosing <a href=\"topic.htm?path=vancomycin-pediatric-drug-information\" class=\"drug drug_pediatric\">vancomycin</a> varies from center to center, usually ranging from 10 to 25 percent.</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>If the child has risk factors for HA-MRSA infection, we suggest empiric therapy with <a href=\"topic.htm?path=vancomycin-pediatric-drug-information\" class=\"drug drug_pediatric\">vancomycin</a> (<a href=\"grade.htm?i=5\" class=\"grade\">Grade 2B</a>).</p><p/><p class=\"bulletIndent2\">(See <a href=\"#H14\" class=\"local\">'For serious infection'</a> above and <a href=\"#H284659487\" class=\"local\">'Vancomycin'</a> above and <a href=\"#H284659633\" class=\"local\">'Clindamycin'</a> above and <a href=\"topic.htm?path=methicillin-resistant-staphylococcus-aureus-infections-in-children-epidemiology-and-clinical-spectrum\" class=\"medical medical_review\">&quot;Methicillin-resistant Staphylococcus aureus infections in children: Epidemiology and clinical spectrum&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>We recommend hospital admission for infants &le;28 days who have been evaluated for invasive infection (<a href=\"grade.htm?i=2\" class=\"grade\">Grade 1B</a>). (See <a href=\"#H24\" class=\"local\">'Treatment of neonates'</a> above and <a href=\"topic.htm?path=febrile-infant-younger-than-90-days-of-age-outpatient-evaluation\" class=\"medical medical_review\">&quot;Febrile infant (younger than 90 days of age): Outpatient evaluation&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Empiric antimicrobial therapy for neonates with suspected invasive staphylococcal infection is based upon the local susceptibility pattern of community-associated <em>S. aureus</em> isolates. <a href=\"topic.htm?path=vancomycin-pediatric-drug-information\" class=\"drug drug_pediatric\">Vancomycin</a> plus <a href=\"topic.htm?path=nafcillin-pediatric-drug-information\" class=\"drug drug_pediatric\">nafcillin</a> plus <a href=\"topic.htm?path=gentamicin-pediatric-drug-information\" class=\"drug drug_pediatric\">gentamicin</a> is one potential regimen; <a href=\"topic.htm?path=linezolid-pediatric-drug-information\" class=\"drug drug_pediatric\">linezolid</a> is an alternative. (See <a href=\"#H24\" class=\"local\">'Treatment of neonates'</a> above.)</p><p/></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/1\" class=\"nounderline abstract_t\">Kaplan SL, Hulten KG, Gonzalez BE, et al. Three-year surveillance of community-acquired Staphylococcus aureus infections in children. Clin Infect Dis 2005; 40:1785.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/2\" class=\"nounderline abstract_t\">Purcell K, Fergie J. Epidemic of community-acquired methicillin-resistant Staphylococcus aureus infections: a 14-year study at Driscoll Children's Hospital. Arch Pediatr Adolesc Med 2005; 159:980.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/3\" class=\"nounderline abstract_t\">Styers D, Sheehan DJ, Hogan P, Sahm DF. Laboratory-based surveillance of current antimicrobial resistance patterns and trends among Staphylococcus aureus: 2005 status in the United States. Ann Clin Microbiol Antimicrob 2006; 5:2.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/4\" class=\"nounderline abstract_t\">Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011; 52:e18.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/5\" class=\"nounderline abstract_t\">Fergie J, Purcell K. The treatment of community-acquired methicillin-resistant Staphylococcus aureus infections. Pediatr Infect Dis J 2008; 27:67.</a></li><li class=\"breakAll\">American Academy of Pediatrics. Staphylococcal infections. In: Red Book: 2015 Report of the Committee on Infectious Diseases, 30th ed, Kimberlin DW, Brady MT, Jackson MA, Long SS (Eds), American Academy of Pediatrics, 2015. p.715.</li><li class=\"breakAll\">Gorwitz RJ, Jernigan DB, Powers JH, et al. Strategies for clinical management of MRSA in the community: Summary of an experts' meeting convened by the Centers for Disease Control and Prevention. 2006. www.cdc.gov/ncidod/dhqp/pdf/ar/CAMRSA_ExpMtgStrategies.pdf (Accessed on September 13, 2011).</li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/8\" class=\"nounderline abstract_t\">Kaplan SL. Treatment of community-associated methicillin-resistant Staphylococcus aureus infections. Pediatr Infect Dis J 2005; 24:457.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/9\" class=\"nounderline abstract_t\">Jimenez-Truque N, Thomsen I, Saye E, Creech CB. Should higher vancomycin trough levels be targeted for invasive community-acquired methicillin-resistant Staphylococcus aureus infections in children? Pediatr Infect Dis J 2010; 29:368.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/10\" class=\"nounderline abstract_t\">Tan TQ, Mason EO Jr, Ou CN, Kaplan SL. Use of intravenous rifampin in neonates with persistent staphylococcal bacteremia. Antimicrob Agents Chemother 1993; 37:2401.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/11\" class=\"nounderline abstract_t\">Baddour LM, Wilson WR, Bayer AS, et al. Infective Endocarditis in Adults: Diagnosis, Antimicrobial Therapy, and Management of Complications: A Scientific Statement for Healthcare Professionals From the American Heart Association. Circulation 2015; 132:1435.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/12\" class=\"nounderline abstract_t\">Pannaraj PS, Hulten KG, Gonzalez BE, et al. Infective pyomyositis and myositis in children in the era of community-acquired, methicillin-resistant Staphylococcus aureus infection. Clin Infect Dis 2006; 43:953.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/13\" class=\"nounderline abstract_t\">Mermel LA, Allon M, Bouza E, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 49:1.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/14\" class=\"nounderline abstract_t\">Naimi TS, LeDell KH, Boxrud DJ, et al. Epidemiology and clonality of community-acquired methicillin-resistant Staphylococcus aureus in Minnesota, 1996-1998. Clin Infect Dis 2001; 33:990.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/15\" class=\"nounderline abstract_t\">Sattler CA, Mason EO Jr, Kaplan SL. Prospective comparison of risk factors and demographic and clinical characteristics of community-acquired, methicillin-resistant versus methicillin-susceptible Staphylococcus aureus infection in children. Pediatr Infect Dis J 2002; 21:910.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/16\" class=\"nounderline abstract_t\">Fergie JE, Purcell K. Community-acquired methicillin-resistant Staphylococcus aureus infections in south Texas children. Pediatr Infect Dis J 2001; 20:860.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/17\" class=\"nounderline abstract_t\">Frank AL, Marcinak JF, Mangat PD, Schreckenberger PC. Community-acquired and clindamycin-susceptible methicillin-resistant Staphylococcus aureus in children. Pediatr Infect Dis J 1999; 18:993.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/18\" class=\"nounderline abstract_t\">Frank AL, Marcinak JF, Mangat PD, et al. Clindamycin treatment of methicillin-resistant Staphylococcus aureus infections in children. Pediatr Infect Dis J 2002; 21:530.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/19\" class=\"nounderline abstract_t\">Siberry GK, Tekle T, Carroll K, Dick J. Failure of clindamycin treatment of methicillin-resistant Staphylococcus aureus expressing inducible clindamycin resistance in vitro. Clin Infect Dis 2003; 37:1257.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/20\" class=\"nounderline abstract_t\">Chambers HF. The changing epidemiology of Staphylococcus aureus? Emerg Infect Dis 2001; 7:178.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/21\" class=\"nounderline abstract_t\">Almer LS, Shortridge VD, Nilius AM, et al. Antimicrobial susceptibility and molecular characterization of community-acquired methicillin-resistant Staphylococcus aureus. Diagn Microbiol Infect Dis 2002; 43:225.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/22\" class=\"nounderline abstract_t\">Paintsil E. Pediatric community-acquired methicillin-resistant Staphylococcus aureus infection and colonization: trends and management. Curr Opin Pediatr 2007; 19:75.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/23\" class=\"nounderline abstract_t\">Zaoutis TE, Toltzis P, Chu J, et al. Clinical and molecular epidemiology of community-acquired methicillin-resistant Staphylococcus aureus infections among children with risk factors for health care-associated infection: 2001-2003. Pediatr Infect Dis J 2006; 25:343.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/24\" class=\"nounderline abstract_t\">Hult&eacute;n KG, Kaplan SL, Gonzalez BE, et al. Three-year surveillance of community onset health care-associated staphylococcus aureus infections in children. Pediatr Infect Dis J 2006; 25:349.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/25\" class=\"nounderline abstract_t\">Braun L, Craft D, Williams R, et al. Increasing clindamycin resistance among methicillin-resistant Staphylococcus aureus in 57 northeast United States military treatment facilities. Pediatr Infect Dis J 2005; 24:622.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/26\" class=\"nounderline abstract_t\">Dietrich DW, Auld DB, Mermel LA. Community-acquired methicillin-resistant Staphylococcus aureus in southern New England children. Pediatrics 2004; 113:e347.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/27\" class=\"nounderline abstract_t\">Kaplan SL. Implications of methicillin-resistant Staphylococcus aureus as a community-acquired pathogen in pediatric patients. Infect Dis Clin North Am 2005; 19:747.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/28\" class=\"nounderline abstract_t\">Pfaller MA, Mendes RE, Castanheira M, et al. Ceftaroline Activity Tested Against Bacterial Isolates Causing Community-acquired Respiratory Tract Infections and Skin and Skin Structure Infections in Pediatric Patients From United States Hospitals: 2012-2014. Pediatr Infect Dis J 2017; 36:486.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/29\" class=\"nounderline abstract_t\">Filippin L, Roisin S, Nonhoff C, et al. Evaluation of the automated Vitek 2 system for detection of various mechanisms of macrolide and lincosamide resistance in Staphylococcus aureus. J Clin Microbiol 2014; 52:4087.</a></li><li class=\"breakAll\">Clinical and Laboratory Standards Institute (CLSI)/National Committee for Clinical Laboratory Standards (NCCLS). 2006. Performance standards for antimicrobial susceptibility testing; sixteenth informational supplement. NCCLS document M100-S16. National Committee for Clinical Laboratory Standards, Wayne, PA.</li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/31\" class=\"nounderline abstract_t\">Tenover FC, Moellering RC Jr. The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus. Clin Infect Dis 2007; 44:1208.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/32\" class=\"nounderline abstract_t\">Hiramatsu K, Hanaki H, Ino T, et al. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother 1997; 40:135.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/33\" class=\"nounderline abstract_t\">Centers for Disease Control and Prevention (CDC). Update: Staphylococcus aureus with reduced susceptibility to vancomycin--United States, 1997. MMWR Morb Mortal Wkly Rep 1997; 46:813.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/34\" class=\"nounderline abstract_t\">Tenover FC, Lancaster MV, Hill BC, et al. Characterization of staphylococci with reduced susceptibilities to vancomycin and other glycopeptides. J Clin Microbiol 1998; 36:1020.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/35\" class=\"nounderline abstract_t\">Ardura MI, Mej&iacute;as A, Katz KS, et al. Daptomycin therapy for invasive Gram-positive bacterial infections in children. Pediatr Infect Dis J 2007; 26:1128.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/36\" class=\"nounderline abstract_t\">Jevitt LA, Smith AJ, Williams PP, et al. In vitro activities of Daptomycin, Linezolid, and Quinupristin-Dalfopristin against a challenge panel of Staphylococci and Enterococci, including vancomycin-intermediate staphylococcus aureus and vancomycin-resistant Enterococcus faecium. Microb Drug Resist 2003; 9:389.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/37\" class=\"nounderline abstract_t\">Espedido BA, Jensen SO, van Hal SJ. Ceftaroline fosamil salvage therapy: an option for reduced-vancomycin-susceptible MRSA bacteraemia. J Antimicrob Chemother 2015; 70:797.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/38\" class=\"nounderline abstract_t\">Leuthner KD, Vidaillac C, Cheung CM, Rybak MJ. In vitro activity of the new multivalent glycopeptide-cephalosporin antibiotic TD-1792 against vancomycin-nonsusceptible Staphylococcus isolates. Antimicrob Agents Chemother 2010; 54:3799.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/39\" class=\"nounderline abstract_t\">Drew RH, Perfect JR, Srinath L, et al. Treatment of methicillin-resistant staphylococcus aureus infections with quinupristin-dalfopristin in patients intolerant of or failing prior therapy. For the Synercid Emergency-Use Study Group. J Antimicrob Chemother 2000; 46:775.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/40\" class=\"nounderline abstract_t\">Moise PA, Forrest A, Birmingham MC, Schentag JJ. The efficacy and safety of linezolid as treatment for Staphylococcus aureus infections in compassionate use patients who are intolerant of, or who have failed to respond to, vancomycin. J Antimicrob Chemother 2002; 50:1017.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/41\" class=\"nounderline abstract_t\">Howden BP, Ward PB, Charles PG, et al. Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin Infect Dis 2004; 38:521.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/42\" class=\"nounderline abstract_t\">Cha R, Brown WJ, Rybak MJ. Bactericidal activities of daptomycin, quinupristin-dalfopristin, and linezolid against vancomycin-resistant Staphylococcus aureus in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob Agents Chemother 2003; 47:3960.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/43\" class=\"nounderline abstract_t\">Sievert DM, Rudrik JT, Patel JB, et al. Vancomycin-resistant Staphylococcus aureus in the United States, 2002-2006. Clin Infect Dis 2008; 46:668.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/44\" class=\"nounderline abstract_t\">Saravolatz LD, Pawlak J, Johnson LB. In vitro susceptibilities and molecular analysis of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus isolates. Clin Infect Dis 2012; 55:582.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/45\" class=\"nounderline abstract_t\">Fortunov RM, Hulten KG, Hammerman WA, et al. Evaluation and treatment of community-acquired Staphylococcus aureus infections in term and late-preterm previously healthy neonates. Pediatrics 2007; 120:937.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/46\" class=\"nounderline abstract_t\">Deresinski S. Counterpoint: Vancomycin and Staphylococcus aureus--an antibiotic enters obsolescence. Clin Infect Dis 2007; 44:1543.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/47\" class=\"nounderline abstract_t\">Lamer C, de Beco V, Soler P, et al. Analysis of vancomycin entry into pulmonary lining fluid by bronchoalveolar lavage in critically ill patients. Antimicrob Agents Chemother 1993; 37:281.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/48\" class=\"nounderline abstract_t\">Moise-Broder PA, Forrest A, Birmingham MC, Schentag JJ. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin Pharmacokinet 2004; 43:925.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/49\" class=\"nounderline abstract_t\">Choice of antibacterial drugs. Treat Guidel Med Lett 2007; 5:33.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/50\" class=\"nounderline abstract_t\">Mohr JF, Murray BE. Point: Vancomycin is not obsolete for the treatment of infection caused by methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2007; 44:1536.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/51\" class=\"nounderline abstract_t\">Stevens DL, Herr D, Lampiris H, et al. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis 2002; 34:1481.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/52\" class=\"nounderline abstract_t\">Kaplan SL, Deville JG, Yogev R, et al. Linezolid versus vancomycin for treatment of resistant Gram-positive infections in children. Pediatr Infect Dis J 2003; 22:677.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/53\" class=\"nounderline abstract_t\">Demirjian A, Finkelstein Y, Nava-Ocampo A, et al. A randomized controlled trial of a vancomycin loading dose in children. Pediatr Infect Dis J 2013; 32:1217.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/54\" class=\"nounderline abstract_t\">Rybak MJ, Lomaestro BM, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adults summary of consensus recommendations from the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Pharmacotherapy 2009; 29:1275.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/55\" class=\"nounderline abstract_t\">Rybak M, Lomaestro B, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 2009; 66:82.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/56\" class=\"nounderline abstract_t\">McKamy S, Hernandez E, Jahng M, et al. Incidence and risk factors influencing the development of vancomycin nephrotoxicity in children. J Pediatr 2011; 158:422.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/57\" class=\"nounderline abstract_t\">Moffett BS, Kim S, Edwards M. Vancomycin nephrotoxicity may be overstated. J Pediatr 2011; 158:865.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/58\" class=\"nounderline abstract_t\">Cies JJ, Shankar V. Nephrotoxicity in patients with vancomycin trough concentrations of 15-20 &mu;g/ml in a pediatric intensive care unit. Pharmacotherapy 2013; 33:392.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/59\" class=\"nounderline abstract_t\">Frymoyer A, Guglielmo BJ, Hersh AL. Desired vancomycin trough serum concentration for treating invasive methicillin-resistant Staphylococcal infections. Pediatr Infect Dis J 2013; 32:1077.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/60\" class=\"nounderline abstract_t\">Chhim RF, Arnold SR, Lee KR. Vancomycin dosing practices, trough concentrations, and predicted area under the curve in children wtih suspected invasive staphylococcal infections. J Pediatric Infect Dis Soc 2013; 2:259.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/61\" class=\"nounderline abstract_t\">McNeil JC, Kok EY, Forbes AR, et al. Healthcare-associated Staphylococcus aureus Bacteremia in Children: Evidence for Reverse Vancomycin Creep and Impact of Vancomycin Trough Values on Outcome. Pediatr Infect Dis J 2016; 35:263.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/62\" class=\"nounderline abstract_t\">Hahn A, Frenck RW Jr, Allen-Staat M, et al. Evaluation of Target Attainment of Vancomycin Area Under the Curve in Children With Methicillin-Resistant Staphylococcus Aureus Bacteremia. Ther Drug Monit 2015; 37:619.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/63\" class=\"nounderline abstract_t\">McNeil JC, Kaplan SL, Vallejo JG. The Influence of the Route of Antibiotic Administration, Methicillin-Susceptibility, Vancomycin Duration and Serum Trough Concentration on Outcomes of Pediatric Staphylococcus aureus Bacteremic Osteoarticular Infection. Pediatr Infect Dis J 2016.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/64\" class=\"nounderline abstract_t\">Karchmer AW. Staphylococcus aureus and vancomycin: the sequel. Ann Intern Med 1991; 115:739.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/65\" class=\"nounderline abstract_t\">Lowy FD. Staphylococcus aureus infections. N Engl J Med 1998; 339:520.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/66\" class=\"nounderline abstract_t\">Gonz&aacute;lez C, Rubio M, Romero-Vivas J, et al. Bacteremic pneumonia due to Staphylococcus aureus: A comparison of disease caused by methicillin-resistant and methicillin-susceptible organisms. Clin Infect Dis 1999; 29:1171.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/67\" class=\"nounderline abstract_t\">Mason EO, Lamberth LB, Hammerman WA, et al. Vancomycin MICs for Staphylococcus aureus vary by detection method and have subtly increased in a pediatric population since 2005. J Clin Microbiol 2009; 47:1628.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/68\" class=\"nounderline abstract_t\">Sakoulas G, Moise-Broder PA, Schentag J, et al. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol 2004; 42:2398.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/69\" class=\"nounderline abstract_t\">Moise-Broder PA, Sakoulas G, Eliopoulos GM, et al. Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy. Clin Infect Dis 2004; 38:1700.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/70\" class=\"nounderline abstract_t\">Sakoulas G, Eliopoulos GM, Moellering RC Jr, et al. Accessory gene regulator (agr) locus in geographically diverse Staphylococcus aureus isolates with reduced susceptibility to vancomycin. Antimicrob Agents Chemother 2002; 46:1492.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/71\" class=\"nounderline abstract_t\">Mart&iacute;nez-Aguilar G, Hammerman WA, Mason EO Jr, Kaplan SL. Clindamycin treatment of invasive infections caused by community-acquired, methicillin-resistant and methicillin-susceptible Staphylococcus aureus in children. Pediatr Infect Dis J 2003; 22:593.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/72\" class=\"nounderline abstract_t\">Mart&iacute;nez-Aguilar G, Avalos-Mishaan A, Hulten K, et al. Community-acquired, methicillin-resistant and methicillin-susceptible Staphylococcus aureus musculoskeletal infections in children. Pediatr Infect Dis J 2004; 23:701.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/73\" class=\"nounderline abstract_t\">Szczesiul JM, Shermock KM, Murtaza UI, Siberry GK. No decrease in clindamycin susceptibility despite increased use of clindamycin for pediatric community-associated methicillin-resistant Staphylococcus aureus skin infections. Pediatr Infect Dis J 2007; 26:852.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/74\" class=\"nounderline abstract_t\">Watanakunakorn C. Clindamycin therapy of Staphylococcus aureus endocarditis. Clinical relapse and development of resistance to clindamycin, lincomycin and erythromycin. Am J Med 1976; 60:419.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/75\" class=\"nounderline abstract_t\">Fiebelkorn KR, Crawford SA, McElmeel ML, Jorgensen JH. Practical disk diffusion method for detection of inducible clindamycin resistance in Staphylococcus aureus and coagulase-negative staphylococci. J Clin Microbiol 2003; 41:4740.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/76\" class=\"nounderline abstract_t\">Panagea S, Perry JD, Gould FK. Should clindamycin be used as treatment of patients with infections caused by erythromycin-resistant staphylococci? J Antimicrob Chemother 1999; 44:581.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/77\" class=\"nounderline abstract_t\">Moellering RC. Linezolid: the first oxazolidinone antimicrobial. Ann Intern Med 2003; 138:135.</a></li><li class=\"breakAll\">Zyvox&reg; (Linezolid) package insert. Pfizer, NY, NY 2008.</li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/79\" class=\"nounderline abstract_t\">Chen CJ, Chiu CH, Lin TY, et al. Experience with linezolid therapy in children with osteoarticular infections. Pediatr Infect Dis J 2007; 26:985.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/80\" class=\"nounderline abstract_t\">Tsiodras S, Gold HS, Sakoulas G, et al. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet 2001; 358:207.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/81\" class=\"nounderline abstract_t\">Ben Mansour EH, Jacob E, Monchi M, et al. Occurrence of MRSA endocarditis during linezolid treatment. Eur J Clin Microbiol Infect Dis 2003; 22:372.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/82\" class=\"nounderline abstract_t\">Corne P, Marchandin H, Macia JC, Jonquet O. Treatment failure of methicillin-resistant Staphylococcus aureus endocarditis with linezolid. Scand J Infect Dis 2005; 37:946.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/83\" class=\"nounderline abstract_t\">Ruiz ME, Guerrero IC, Tuazon CU. Endocarditis caused by methicillin-resistant Staphylococcus aureus: treatment failure with linezolid. Clin Infect Dis 2002; 35:1018.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/84\" class=\"nounderline abstract_t\">Gales AC, Sader HS, Andrade SS, et al. Emergence of linezolid-resistant Staphylococcus aureus during treatment of pulmonary infection in a patient with cystic fibrosis. Int J Antimicrob Agents 2006; 27:300.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/85\" class=\"nounderline abstract_t\">Deville JG, Adler S, Azimi PH, et al. Linezolid versus vancomycin in the treatment of known or suspected resistant gram-positive infections in neonates. Pediatr Infect Dis J 2003; 22:S158.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/86\" class=\"nounderline abstract_t\">Kaplan SL, Afghani B, Lopez P, et al. Linezolid for the treatment of methicillin-resistant Staphylococcus aureus infections in children. Pediatr Infect Dis J 2003; 22:S178.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/87\" class=\"nounderline abstract_t\">Meka VG, Gold HS. Antimicrobial resistance to linezolid. Clin Infect Dis 2004; 39:1010.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/88\" class=\"nounderline abstract_t\">S&aacute;nchez Garc&iacute;a M, De la Torre MA, Morales G, et al. Clinical outbreak of linezolid-resistant Staphylococcus aureus in an intensive care unit. JAMA 2010; 303:2260.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/89\" class=\"nounderline abstract_t\">Lyseng-Williamson KA, Goa KL. Linezolid: in infants and children with severe Gram-positive infections. Paediatr Drugs 2003; 5:419.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/90\" class=\"nounderline abstract_t\">Saiman L, Goldfarb J, Kaplan SA, et al. Safety and tolerability of linezolid in children. Pediatr Infect Dis J 2003; 22:S193.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/91\" class=\"nounderline abstract_t\">Meissner HC, Townsend T, Wenman W, et al. Hematologic effects of linezolid in young children. Pediatr Infect Dis J 2003; 22:S186.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/92\" class=\"nounderline abstract_t\">Aneziokoro CO, Cannon JP, Pachucki CT, Lentino JR. The effectiveness and safety of oral linezolid for the primary and secondary treatment of osteomyelitis. J Chemother 2005; 17:643.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/93\" class=\"nounderline abstract_t\">Jones SJ, Nichols KR, DeYoung HL, et al. Linezolid-Associated Thrombocytopenia in Children With Renal Impairment. J Pediatric Infect Dis Soc 2015; 4:272.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/94\" class=\"nounderline abstract_t\">Bishop E, Melvani S, Howden BP, et al. Good clinical outcomes but high rates of adverse reactions during linezolid therapy for serious infections: a proposed protocol for monitoring therapy in complex patients. Antimicrob Agents Chemother 2006; 50:1599.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/95\" class=\"nounderline abstract_t\">Birmingham MC, Rayner CR, Meagher AK, et al. Linezolid for the treatment of multidrug-resistant, gram-positive infections: experience from a compassionate-use program. Clin Infect Dis 2003; 36:159.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/96\" class=\"nounderline abstract_t\">Linam WM, Wesselkamper K, Gerber MA. Peripheral neuropathy in an adolescent treated with linezolid. Pediatr Infect Dis J 2009; 28:149.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/97\" class=\"nounderline abstract_t\">Nambiar S, Rellosa N, Wassel RT, et al. Linezolid-associated peripheral and optic neuropathy in children. Pediatrics 2011; 127:e1528.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/98\" class=\"nounderline abstract_t\">Werner G, Cuny C, Schmitz FJ, Witte W. Methicillin-resistant, quinupristin-dalfopristin-resistant Staphylococcus aureus with reduced sensitivity to glycopeptides. J Clin Microbiol 2001; 39:3586.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/99\" class=\"nounderline abstract_t\">Eliopoulos GM. Quinupristin-dalfopristin and linezolid: evidence and opinion. Clin Infect Dis 2003; 36:473.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/100\" class=\"nounderline abstract_t\">Vouillamoz J, Entenza JM, F&eacute;ger C, et al. Quinupristin-dalfopristin combined with beta-lactams for treatment of experimental endocarditis due to Staphylococcus aureus constitutively resistant to macrolide-lincosamide-streptogramin B antibiotics. Antimicrob Agents Chemother 2000; 44:1789.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/101\" class=\"nounderline abstract_t\">Loeffler AM, Drew RH, Perfect JR, et al. Safety and efficacy of quinupristin/dalfopristin for treatment of invasive Gram-positive infections in pediatric patients. Pediatr Infect Dis J 2002; 21:950.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/102\" class=\"nounderline abstract_t\">Fuchs PC, Barry AL, Brown SD. In vitro bactericidal activity of daptomycin against staphylococci. J Antimicrob Chemother 2002; 49:467.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/103\" class=\"nounderline abstract_t\">Carpenter CF, Chambers HF. Daptomycin: another novel agent for treating infections due to drug-resistant gram-positive pathogens. Clin Infect Dis 2004; 38:994.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/104\" class=\"nounderline abstract_t\">Arbeit RD, Maki D, Tally FP, et al. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis 2004; 38:1673.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/105\" class=\"nounderline abstract_t\">Fowler VG Jr, Boucher HW, Corey GR, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 2006; 355:653.</a></li><li class=\"breakAll\">ClinicalTrials.gov. Comparative evaluation of the safety &amp; efficacy of daptomycin versus SOC in 1 - 17 year olds with Staphylococcus aureus bacteremia (MK-3009-005). https://clinicaltrials.gov/ct2/show/NCT01728376 (Accessed on October 13, 2015).</li><li class=\"breakAll\">Cubicin (daptomycin for injection). United States Prescribing Information. Revised September, 2017. US Food &amp; Drug Administration. Available online: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm (Accessed on September 07, 2017).</li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/108\" class=\"nounderline abstract_t\">Silverman JA, Mortin LI, Vanpraagh AD, et al. Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact. J Infect Dis 2005; 191:2149.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/109\" class=\"nounderline abstract_t\">Sakoulas G, Eliopoulos GM, Alder J, Eliopoulos CT. Efficacy of daptomycin in experimental endocarditis due to methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2003; 47:1714.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/110\" class=\"nounderline abstract_t\">Abdel-Rahman SM, Benziger DP, Jacobs RF, et al. Single-dose pharmacokinetics of daptomycin in children with suspected or proved gram-positive infections. Pediatr Infect Dis J 2008; 27:330.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/111\" class=\"nounderline abstract_t\">Abdel-Rahman SM, Chandorkar G, Akins RL, et al. Single-dose pharmacokinetics and tolerability of daptomycin 8 to 10 mg/kg in children aged 2 to 6 years with suspected or proved Gram-positive infections. Pediatr Infect Dis J 2011; 30:712.</a></li><li class=\"breakAll\">Chandorkar G, Abdel-Rahman S, Jacobs R, et al. Pharmacokinetics (PK) and safety of 8 and 10 mg/kg of daptomycin in pediatric patients aged 2 to 6 years (abstract 1243). Data presented October 31, 2009.</li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/113\" class=\"nounderline abstract_t\">Bradley J, Glasser C, Patino H, et al. Daptomycin for Complicated Skin Infections: A Randomized Trial. Pediatrics 2017; 139.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/114\" class=\"nounderline abstract_t\">Sakoulas G, Alder J, Thauvin-Eliopoulos C, et al. Induction of daptomycin heterogeneous susceptibility in Staphylococcus aureus by exposure to vancomycin. Antimicrob Agents Chemother 2006; 50:1581.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/115\" class=\"nounderline abstract_t\">Jacobson LM, Milstone AM, Zenilman J, et al. Daptomycin therapy failure in an adolescent with methicillin-resistant Staphylococcus aureus bacteremia. Pediatr Infect Dis J 2009; 28:445.</a></li><li class=\"breakAll\">ClinicalTrials.gov. Safety and efficacy of daptomycin compared to active comparator in pediatric participants with acute hematogenous osteomyelitis (AHO) (MK-3009-006). www.clinicaltrials.gov/ct2/show/NCT01922011 (Accessed on October 13, 2015).</li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/117\" class=\"nounderline abstract_t\">Ardati KO, Thirumoorthi MC, Dajani AS. Intravenous trimethoprim-sulfamethoxazole in the treatment of serious infections in children. J Pediatr 1979; 95:801.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/118\" class=\"nounderline abstract_t\">Adra M, Lawrence KR. Trimethoprim/sulfamethoxazole for treatment of severe Staphylococcus aureus infections. Ann Pharmacother 2004; 38:338.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/119\" class=\"nounderline abstract_t\">Iyer S, Jones DH. Community-acquired methicillin-resistant Staphylococcus aureus skin infection: a retrospective analysis of clinical presentation and treatment of a local outbreak. J Am Acad Dermatol 2004; 50:854.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/120\" class=\"nounderline abstract_t\">Markowitz N, Quinn EL, Saravolatz LD. Trimethoprim-sulfamethoxazole compared with vancomycin for the treatment of Staphylococcus aureus infection. Ann Intern Med 1992; 117:390.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/121\" class=\"nounderline abstract_t\">Paul M, Bishara J, Yahav D, et al. Trimethoprim-sulfamethoxazole versus vancomycin for severe infections caused by meticillin resistant Staphylococcus aureus: randomised controlled trial. BMJ 2015; 350:h2219.</a></li><li class=\"breakAll\">Ceftaroline . US Food &amp; Drug Administration (FDA) approved product information. Revised May, 2016. US Food &amp; Drug Administration. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm (Accessed on June 06, 2016).</li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/123\" class=\"nounderline abstract_t\">Brown SD, Traczewski MM. In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing. Antimicrob Agents Chemother 2009; 53:1271.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/124\" class=\"nounderline abstract_t\">Korczowski B, Antadze T, Giorgobiani M, et al. A Multicenter, Randomized, Observer-blinded, Active-controlled Study to Evaluate the Safety and Efficacy of Ceftaroline Versus Comparator in Pediatric Patients With Acute Bacterial Skin and Skin Structure Infection. Pediatr Infect Dis J 2016; 35:e239.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/125\" class=\"nounderline abstract_t\">Cannavino CR, Nemeth A, Korczowski B, et al. A Randomized, Prospective Study of Pediatric Patients With Community-acquired Pneumonia Treated With Ceftaroline Versus Ceftriaxone. Pediatr Infect Dis J 2016; 35:752.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-in-children-treatment-of-invasive-infections/abstract/126\" class=\"nounderline abstract_t\">Blumer JL, Ghonghadze T, Cannavino C, et al. A Multicenter, Randomized, Observer-blinded, Active-controlled Study Evaluating the Safety and Effectiveness of Ceftaroline Compared With Ceftriaxone Plus Vancomycin in Pediatric Patients With Complicated Community-acquired Bacterial Pneumonia. Pediatr Infect Dis J 2016; 35:760.</a></li><li class=\"breakAll\">ClinicalTrials.gov. Ceftaroline for treatment of hematogenously acquired Staphylococcus aureus osteomyelitis in children. https://clinicaltrials.gov/ct2/show/NCT02335905 (Accessed on June 06, 2016).</li><li class=\"breakAll\">ClinicalTrials.gov. Safety, tolerability and efficacy of ceftaroline in paediatrics with late-onset sepsis. https://clinicaltrials.gov/ct2/show/NCT02424734 (Accessed on June 06, 2016).</li></ol></div><div id=\"topicVersionRevision\">Topic 6057 Version 37.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H27\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H11\" id=\"outline-link-H11\">TREATMENT APPROACH</a></li><li><a href=\"#H12\" id=\"outline-link-H12\">EMPIRIC THERAPY</a><ul><li><a href=\"#H13\" id=\"outline-link-H13\">For critically ill</a></li><li><a href=\"#H14\" id=\"outline-link-H14\">For serious infection</a><ul><li><a href=\"#H15\" id=\"outline-link-H15\">- Bacteremia</a></li><li><a href=\"#H16\" id=\"outline-link-H16\">- Osteomyelitis</a></li><li><a href=\"#H17\" id=\"outline-link-H17\">- Pneumonia</a></li><li><a href=\"#H18\" id=\"outline-link-H18\">- Skin and soft tissue</a></li></ul></li></ul></li><li><a href=\"#H19\" id=\"outline-link-H19\">DEFINITIVE THERAPY</a><ul><li><a href=\"#H20\" id=\"outline-link-H20\">MRSA infections</a></li><li><a href=\"#H21\" id=\"outline-link-H21\">VISA infections</a></li><li><a href=\"#H22\" id=\"outline-link-H22\">VRSA infections</a></li></ul></li><li><a href=\"#H23\" id=\"outline-link-H23\">DURATION OF THERAPY</a></li><li><a href=\"#H24\" id=\"outline-link-H24\">TREATMENT OF NEONATES</a></li><li><a href=\"#H25\" id=\"outline-link-H25\">TREATMENT FAILURE</a></li><li><a href=\"#H284659481\" id=\"outline-link-H284659481\">ANTIMICROBIAL AGENTS</a><ul><li><a href=\"#H284659487\" id=\"outline-link-H284659487\">Vancomycin</a></li><li><a href=\"#H284659633\" id=\"outline-link-H284659633\">Clindamycin</a><ul><li><a href=\"#H2497450507\" id=\"outline-link-H2497450507\">- Indications</a></li><li><a href=\"#H284659711\" id=\"outline-link-H284659711\">- Inducible resistance</a></li></ul></li><li><a href=\"#H284659717\" id=\"outline-link-H284659717\">Linezolid</a></li><li><a href=\"#H284659723\" id=\"outline-link-H284659723\">Quinupristin-dalfopristin</a></li><li><a href=\"#H284659729\" id=\"outline-link-H284659729\">Daptomycin</a></li><li><a href=\"#H284659735\" id=\"outline-link-H284659735\">Trimethoprim-sulfamethoxazole</a></li><li><a href=\"#H425217035\" id=\"outline-link-H425217035\">Ceftaroline</a></li><li><a href=\"#H284659741\" id=\"outline-link-H284659741\">Investigational therapies</a></li></ul></li><li><a href=\"#H4093177008\" id=\"outline-link-H4093177008\">SOCIETY GUIDELINE LINKS</a></li><li><a href=\"#PATIENT_INFORMATION\" id=\"outline-link-H26\">INFORMATION FOR PATIENTS</a></li><li><a href=\"#H27\" id=\"outline-link-H27\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"PEDS/6057|PIC\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"PICTURES\">PICTURES</a></div><ul><li><a href=\"image.htm?imageKey=ID/114732\" class=\"graphic graphic_picture\">- Detection of inducible clindamycin resistance using the D test</a></li></ul></li><li><div id=\"PEDS/6057|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=PEDS/78349\" class=\"graphic graphic_table\">- Rx serious MRSA child</a></li><li><a href=\"image.htm?imageKey=PEDS/61437\" class=\"graphic graphic_table\">- Empiric rx serious SA child</a></li><li><a href=\"image.htm?imageKey=PEDS/69174\" class=\"graphic graphic_table\">- Rx serious VISA child</a></li><li><a href=\"image.htm?imageKey=PEDS/64140\" class=\"graphic graphic_table\">- Neonatal doses MRSA</a></li><li><a href=\"image.htm?imageKey=PEDS/57379\" class=\"graphic graphic_table\">- Rx serious MSSA child</a></li><li><a href=\"image.htm?imageKey=PEDS/63973\" class=\"graphic graphic_table\">- Oral antibiotics suspected MRSA SSTI children</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=bacterial-meningitis-in-the-neonate-treatment-and-outcome\" class=\"medical medical_review\">Bacterial meningitis in the neonate: Treatment and outcome</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=community-acquired-pneumonia-in-children-outpatient-treatment\" class=\"medical medical_review\">Community-acquired pneumonia in children: Outpatient treatment</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=febrile-infant-younger-than-90-days-of-age-outpatient-evaluation\" class=\"medical medical_review\">Febrile infant (younger than 90 days of age): Outpatient evaluation</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=hematogenous-osteomyelitis-in-children-evaluation-and-diagnosis\" class=\"medical medical_review\">Hematogenous osteomyelitis in children: Evaluation and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=hematogenous-osteomyelitis-in-children-management\" class=\"medical medical_review\">Hematogenous osteomyelitis in children: Management</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=management-and-prognosis-of-parapneumonic-effusion-and-empyema-in-children\" class=\"medical medical_review\">Management and prognosis of parapneumonic effusion and empyema in children</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia\" class=\"medical medical_review\">Methicillin-resistant Staphylococcus aureus (MRSA) in adults: Treatment of bacteremia</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-skin-and-soft-tissue-infections\" class=\"medical medical_review\">Methicillin-resistant Staphylococcus aureus (MRSA) in adults: Treatment of skin and soft tissue infections</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=methicillin-resistant-staphylococcus-aureus-mrsa-microbiology\" class=\"medical medical_review\">Methicillin-resistant Staphylococcus aureus (MRSA): Microbiology</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=methicillin-resistant-staphylococcus-aureus-infections-in-children-epidemiology-and-clinical-spectrum\" class=\"medical medical_review\">Methicillin-resistant Staphylococcus aureus infections in children: Epidemiology and clinical spectrum</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=neonatal-pneumonia\" class=\"medical medical_review\">Neonatal pneumonia</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-antibacterial-susceptibility-testing\" class=\"medical medical_review\">Overview of antibacterial susceptibility testing</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=methicillin-resistant-staphylococcus-aureus-mrsa-beyond-the-basics\" class=\"medical medical_patient\">Patient education: Methicillin-resistant Staphylococcus aureus (MRSA) (Beyond the Basics)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pneumonia-in-children-inpatient-treatment\" class=\"medical medical_review\">Pneumonia in children: Inpatient treatment</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=serotonin-syndrome-serotonin-toxicity\" class=\"medical medical_review\">Serotonin syndrome (serotonin toxicity)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=society-guideline-links-methicillin-resistant-staphylococcus-aureus\" class=\"medical medical_society_guidelines\">Society guideline links: Methicillin-resistant Staphylococcus aureus</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=staphylococcus-aureus-bacteremia-in-children-management-and-outcome\" class=\"medical medical_review\">Staphylococcus aureus bacteremia in children: Management and outcome</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin\" class=\"medical medical_review\">Staphylococcus aureus bacteremia with reduced susceptibility to vancomycin</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=suspected-staphylococcus-aureus-and-streptococcal-skin-and-soft-tissue-infections-in-children-greater-than28-days-evaluation-and-management\" class=\"medical medical_review\">Suspected Staphylococcus aureus and streptococcal skin and soft tissue infections in children &gt;28 days: Evaluation and management</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=urinary-tract-infections-in-neonates\" class=\"medical medical_review\">Urinary tract infections in neonates</a></li></ul></div></div>","javascript":null}